National Comprehensive Cancer Network®

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®)

Lung Cancer Screening

Version 1.2014

NCCN.org

Continue

NCCN Guidelines Version 1.2014 Panel Members
Lung Cancer Screening

NCCN Guidelines Index
LCS Table of Contents
Discussion

* Douglas E. Wood, MD/Chair ¶
University of Washington/
Seattle Cancer Care Alliance

Ella Kazerooni, MD/Vice Chair ф
University of Michigan
Comprehensive Cancer Center

Scott L. Baum, MD ф
University of Tennessee Health Science Center

Mark M. Dransfield, MD Ξ
University of Alabama at Birmingham Comprehensive Cancer Center

George A. Eapen, MD Ξ
The University of Texas
MD Anderson Cancer Center

David S. Ettinger, MD †
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Lifang Hou, MD, PhD &
Robert H. Lurie Comprehensive Cancer Center of Northwestern University

David Jackman, MD †
Dana-Farber/Brigham and Women's Cancer Center

Donald Klippenstein, MD ф
Moffitt Cancer Center

Rudy P. Lackner, MD ¶
UNMC Eppley Cancer Center at The Nebraska Medical Center

Lorriana E. Leard, MD Ξ
UCSF Helen Diller Family Comprehensive Cancer Center

Ann N. C. Leung, MD ф
Stanford Comprehensive Cancer Center

Pierre P. Massion, MD Ξ
Vanderbilt-Ingram Cancer Center

Bryan F. Meyers, MD, MPH ¶
Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine

Reginald F. Munden, MD, DMD, MBA ф
The University of Texas
MD Anderson Cancer Center

Gregory A. Otterson, MD †
The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute

Kimberly Peairs, MD Þ
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Sudhakar Pipavath, MD ф
University of Washington/
Seattle Cancer Care Alliance

Christie Pratt-Pozo, MA, DHSc ¥
Moffitt Cancer Center

Chakravarthy Reddy, MD Ξ Þ
Huntsman Cancer Institute
at the University of Utah

Mary E. Reid, PhD &
Roswell Park Cancer Institute

Arnold J. Rotter, MD ф
City of Hope Comprehensive Cancer Center

Matthew B. Schabath, PhD &
Moffitt Cancer Center

Lecia V. Sequist, MD, MPH †
Massachusetts General Hospital Cancer Center

Betty C. Tong, MD, MHS ¶
Duke Cancer Institute

William D. Travis, MD ≠
Memorial Sloan-Kettering Cancer Center

Michael Unger, MD Ξ
Fox Chase Cancer Center

Stephen C. Yang, MD ¶
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

NCCN
Kristina Gregory, RN, MSN, OCN
Miranda Hughes, PhD

[NCCN Guidelines Panel Disclosures]

Continue

¶ Surgical oncology
† Medical oncology
& Epidemiology
ф Diagnostic radiology
Ξ Pulmonary medicine
‡ Hematology/Oncology
Þ Internal medicine
¥ Patient advocacy
≠ Pathology
* Writing committee

NCCN Guidelines Version 1.2014 Table of Contents
Lung Cancer Screening

Clinical Trials: NCCN believes that the best management for any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

To find clinical trials online at NCCN Member Institutions, click here: nccn.org/clinical_trials/physician.html.

NCCN Categories of Evidence and Consensus: All recommendations are category 2A unless otherwise specified.

See NCCN Categories of Evidence and Consensus.

NCCN Guidelines Version 1.2014 Updates Lung Cancer Screening

NCCN Guidelines Index
LCS Table of Contents
Discussion

Summary of changes in the 1.2014 version of the NCCN Guidelines for Lung Cancer Screening from the 1.2013 version include:

LCS-1
- **The following sentence added to footnote "b": Chest x-ray is not recommended for lung cancer screening.**
- **The following sentence added to footnote "c": Lung cancer screening should not be considered a substitute for smoking cessation.**

LCS-2
- **Footnote "h" clarified by adding a link to Table 2. Also, the following sentence was added: There should be a systematic process for appropriate follow-up. (also applies to LCS-3 through LCS-6)**

LCS-3
- **Evaluation of Screening Findings: ≤4 mm changed to <6 mm. The category of >4-6 mm was removed. The category of >6-8 mm changed to 6-8 mm.**
- **Footnote "p" added: Tissue samples need to be adequate for both histology and molecular testing. Travis WD, et al. Diagnosis of lung cancer in small biopsies and cytology: Implications of the 2011 International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society Classification. Arch Pathol Lab Med 2013;137:668-684. (also applies to LCS-4 and LCS-6).**

LCS-4
- **Evaluation of Screening Findings: <5 mm changed to ≤5 mm and 5-10 mm changed to >5-10 mm.**
- **Footnote "q" added: It is crucial that all GGO/GGN/nonsolid lesions must be reviewed at thin (<1.5 mm) slices to exclude any solid components. Any solid component in the nodule requires management of the lesion with the part-solid recommendations (see LCS-3).**

LCS-5
- **New page added to address the evaluation and management of multiple GGO/GGNs.**

LCS-A
- **Risks: "procedures" added to Unnecessary testing.**



[a] It is recommended that institutions performing lung cancer screening use a multidisciplinary approach that includes the specialties of thoracic radiology, pulmonary medicine, and thoracic surgery.

[b] Lung cancer screening is appropriate to consider for those high-risk patients who are potential candidates for definitive treatment. Chest x-ray is not recommended for lung cancer screening.

[c] All current smokers should be advised to quit smoking, and former smokers should be advised to remain abstinent from smoking (http://www.surgeongeneral.gov/initiatives/tobacco/index.html). For additional cessation support and resources, smokers can be referred to http://www.smokefree.gov. Lung cancer screening should not be considered a substitute for smoking cessation.

[d] Documented high radon exposure.

[e] Agents that are identified specifically as carcinogens targeting the lungs: silica, cadmium, asbestos, arsenic, beryllium, chromium, diesel fumes, nickel, coal smoke, and soot.

[f] There is increased risk of developing new primary lung cancer among survivors of lung cancer, lymphomas, cancers of the head and neck, or smoking-related cancers.

[g] Individuals exposed to second-hand smoke have a highly variable exposure to the carcinogens, with varying evidence for increased risk after this variable exposure. Therefore, second-hand smoke is not independently considered a risk factor for lung cancer screening.

Note: All recommendations are category 2A unless otherwise indicated.
Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.



[h] All screening and follow-up CT scans should be performed at low dose (100-120 kVp & 40-60 mAs or less), unless evaluating mediastinal abnormalities or lymph nodes, where standard-dose CT with IV contrast might be appropriate (See Table 2). There should be a systematic process for appropriate follow-up.

[i] Without benign pattern of calcification, fat in nodule as in hamartoma, or features suggesting inflammatory etiology. When multiple nodules are present and occult infection or inflammation is a possibility, an added option is a course of a broad-spectrum antibiotic with anaerobic coverage, followed by LDCT 1-2 months later.

[j] If new nodule at annual or follow-up LDCT, see LCS-6. New nodule is defined as ≥3 mm in mean diameter.

[k] There is uncertainty about the appropriate duration of screening and the age at which screening is no longer appropriate.

Note: All recommendations are category 2A unless otherwise indicated.
Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.



[h] All screening and follow-up CT scans should be performed at low dose (100-120 kVp & 40-60 mAs or less), unless evaluating mediastinal abnormalities or lymph nodes, where standard dose CT with IV contrast might be appropriate. (See Table 2). There should be a systematic process for appropriate follow-up.

[i] Without benign pattern of calcification, fat in nodule as in hamartoma, or features suggesting inflammatory etiology. When multiple nodules are present and occult infection or inflammation is a possibility, an added option is a course of a broad-spectrum antibiotic with anaerobic coverage, followed by LDCT 1-2 months later.

[j] If new nodule at annual or follow-up LDCT, see LCS-6. New nodule is defined as ≥ 3 mm in mean diameter.

[k] There is uncertainty about the appropriate duration of screening and the age at which screening is no longer appropriate.

[l] Mean diameter is the mean of the longest diameter of the nodule and its perpendicular diameter.

[m] Criteria for suspicion of malignancy: hypermetabolism higher than the background of surrounding lung parenchyma, regardless of absolute SUV.

[n] For nodules <15 mm: increase in mean diameter ≥2 mm in any nodule or in the solid portion of a part solid nodule compared to baseline scan. For nodules ≥15 mm: increase in mean diameter of ≥15% compared to baseline scan.

[o] Rapid increase in size should raise suspicion of inflammatory etiology or malignancy other than non-small cell lung cancer.

[p] Tissue samples need to be adequate for both histology and molecular testing. Travis WD, et al. Diagnosis of lung cancer in small biopsies and cytology: Implications of the 2011 International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society Classification. Arch Pathol Lab Med 2013;137:668-684.

Note: All recommendations are category 2A unless otherwise indicated.
Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.



[h] All screening and follow-up CT scans should be performed at low dose (100-120 kVp & 40-60 mAs or less), unless evaluating mediastinal abnormalities or lymph nodes, where standard dose CT with IV contrast might be appropriate. (See Table 2). There should be a systematic process for appropriate follow-up.

[i] Without benign pattern of calcification, fat in nodule as in hamartoma, or features suggesting inflammatory etiology. When multiple nodules are present and occult infection or inflammation is a possibility, an added option is a course of a broad-spectrum antibiotic with anaerobic coverage, followed by LDCT 1-2 months later.

[j] If new nodule at annual or follow-up LDCT, see LCS-6. New nodule is defined as ≥3 mm in mean diameter.

[k] There is uncertainty about the appropriate duration of screening and the age at which screening is no longer appropriate.

[l] Mean diameter is the mean of the longest diameter of the nodule and its perpendicular diameter.

[n] For nodules <15 mm: increase in mean diameter ≥2 mm in any nodule or in the solid portion of a part solid nodule compared to baseline scan. For nodules ≥15 mm: increase in mean diameter of ≥15% compared to baseline scan.

[o] Rapid increase in size should raise suspicion of inflammatory etiology or malignancy other than NSCLC.

[p] Tissue samples need to be adequate for both histology and molecular testing. Travis WD, et al. Diagnosis of lung cancer in small biopsies and cytology: Implications of the 2011 International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society Classification. Arch Pathol Lab Med 2013;137:668-684.

[q] It is crucial that all GGO/GGN/nonsolid lesions must be reviewed at thin (<1.5 mm) slices to exclude any solid components. Any solid component in the nodule requires management of the lesion with the part-solid recommendations (see LCS-3).

Note: All recommendations are category 2A unless otherwise indicated.
Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.



[h] All screening and follow-up CT scans should be performed at low dose (100-120 kVp & 40-60 mAs or less), unless evaluating mediastinal abnormalities or lymph nodes, where standard dose CT with IV contrast might be appropriate. (See Table 2). There should be a systematic process for appropriate follow-up.

[i] Without benign pattern of calcification, fat in nodule as in hamartoma, or features suggesting inflammatory etiology. When multiple nodules are present and occult infection or inflammation is a possibility, an added option is a course of a broad-spectrum antibiotic with anaerobic coverage, followed by LDCT 1-2 months later.

[j] If new nodule at annual or follow-up LDCT, see LCS-6. New nodule is defined as ≥3 mm in mean diameter.

[k] There is uncertainty about the appropriate duration of screening and the age at which screening is no longer appropriate.

[l] Mean diameter is the mean of the longest diameter of the nodule and its perpendicular diameter.

[n] For nodules <15 mm: increase in mean diameter ≥2 mm in any nodule or in the solid portion of a part solid nodule compared to baseline scan. For nodules ≥15 mm: increase in mean diameter of ≥15% compared to baseline scan.

[o] Rapid increase in size should raise suspicion of inflammatory etiology or malignancy other than NSCLC.

[q] It is crucial that all GGO/GGN/Nonsolid lesions must be reviewed at thin (<1.5 mm) slices to exclude any solid components. Any solid component in the nodule requires management of the lesion with the part-solid recommendations (see LCS-3).

Note: All recommendations are category 2A unless otherwise indicated.
Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

EVALUATION OF SCREENING FINDINGS

FOLLOW-UP OF SCREENING FINDINGS



[h] All screening and follow-up CT scans should be performed at low dose (100-120 kVp & 40-60 mAs or less), unless evaluating mediastinal abnormalities or lymph nodes, where standard dose CT with IV contrast might be appropriate. (See Table 2). There should be a systematic process for appropriate follow-up.

[i] Without benign pattern of calcification, fat in nodule as in hamartoma, or features suggesting inflammatory etiology. When multiple nodules are present and occult infection or inflammation is a possibility, an added option is a course of a broad-spectrum antibiotic with anaerobic coverage, followed by LDCT 1-2 months later.

[k] There is uncertainty about the appropriate duration of screening and the age at which screening is no longer appropriate.

[m] Criteria for suspicion of malignancy: hypermetabolism higher than the background of surrounding lung parenchyma, regardless of absolute SUV.

[o] Rapid increase in size should raise suspicion of inflammatory etiology or malignancy other than NSCLC.

[p] Tissue samples need to be adequate for both histology and molecular testing. Travis WD, et al. Diagnosis of lung cancer in small biopsies and cytology: Implications of the 2011 International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society Classification. Arch Pathol Lab Med 2013;137:668-684.

[r] New nodule is defined as ≥3 mm in mean diameter.

[s] PET-CT for lesions >8 mm.

Note: All recommendations are category 2A unless otherwise indicated.
Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

RISKS/BENEFITS OF LUNG CANCER SCREENING*

RISKS
- Futile detection of small aggressive tumors or indolent disease
- Quality of life
  - Anxiety of test findings
- Physical complications from diagnostic workup
- False-positive results
- False-negative results
- Unnecessary testing and procedures
- Radiation exposure
- Cost
- Incidental lesions

BENEFITS
- Decreased lung cancer mortality
- Quality of life
  - Reduction in disease-related morbidity
  - Reduction in treatment-related morbidity
  - Improvement in healthy lifestyles
  - Reduction in anxiety/psychosocial burden

*See Discussion for more detailed information.

Note: All recommendations are category 2A unless otherwise indicated.
Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

Discussion

This discussion is being updated to correspond with the newly updated algorithm. Last updated 06/15/12

NCCN Categories of Evidence and Consensus

Category 1: Based upon high-level evidence, there is uniform NCCN consensus that the intervention is appropriate.

Category 2A: Based upon lower-level evidence, there is uniform NCCN consensus that the intervention is appropriate.

Category 2B: Based upon lower-level evidence, there is NCCN consensus that the intervention is appropriate.

Category 3: Based upon any level of evidence, there is major NCCN disagreement that the intervention is appropriate.

All recommendations are category 2A unless otherwise noted.

Table of Contents

Overview

Lung cancer is the leading cause of cancer-related mortality in the United States and worldwide.[1-4] In 2012, it is estimated that 160,300 deaths (87,700 in men, 72,600 in women) from lung cancer will occur in the United States.[4] Five-year survival rates for lung cancer are only 15.9%, partly because most patients have advanced-stage lung cancer at initial diagnosis (http://seer.cancer.gov/statfacts/html/lungb.html).[5]

These facts, combined with the success of screening in improving outcomes in cervical, colon, and breast cancers, have been the impetus for studies to develop an effective lung cancer screening test.[6,7] Ideally, effective screening will lead to earlier detection of lung cancer (before patients have symptoms and when treatment is more likely to be effective) and will decrease mortality.[8] Currently, most lung cancer is diagnosed clinically when patients present with symptoms (such as persistent cough, chest pain, weight loss); unfortunately, patients with these symptoms usually have advanced lung cancer.

Early detection of lung cancer is an important opportunity for decreasing mortality. Considerable interest has been shown in developing screening tools to detect early stage lung cancer. Recent data support using spiral (helical) low-dose computed tomography (LDCT) of the chest to screen select patients who are at high risk for lung cancer (http://www.cancer.gov/clinicaltrials/noteworthy-trials/nlst).[8-10]

The NCCN Lung Cancer Screening Panel developed this screening guideline in 2011 based on the current body of evidence.[8] These guidelines 1) describe risk factors for lung cancer; 2) recommend criteria for selecting high-risk individuals for screening; 3) provide recommendations for evaluation and follow-up of nodules found during screening; 4) discuss the accuracy of LDCT screening protocols and imaging modalities; and 5) discuss the benefits and risks of screening.

Screening for Non–Small Cell Lung Cancer

Most lung cancers (85%) are classified as non–small cell lung cancer (NSCLC); small cell lung cancer occurs in 13% to 15% of patients (see the NCCN Guidelines for NSCLC and Small Cell Lung Cancer). Thus, these NCCN Lung Cancer Screening guidelines mainly refer to detection of NSCLC. Other types of cancer can metastasize to the lungs (eg, breast cancer), and there are also less common cancers of the lung or chest (eg, malignant pleural mesothelioma, thymic carcinoma). Lung cancer screening may also detect noncancerous conditions of the thorax (eg, aortic aneurysm, coronary artery calcification) and tumors or benign disease outside of the chest (eg, renal cell carcinoma, adrenal adenoma).

The goal of screening is to detect disease at a stage when it is not causing symptoms and when treatment is most successful. Screening should benefit the individual by increasing life expectancy and increasing quality of life. The rate of false-positive results should be low to prevent unnecessary additional testing. The large fraction of the population without the disease should not be harmed (low risk), and the screening test should not be so expensive that it places an onerous burden on the health care system. Thus, the screening test should: 1) improve outcome; 2) be scientifically validated (eg, have acceptable levels of sensitivity and specificity); and 3) be low risk, reproducible, accessible, and cost effective.

Perhaps the most difficult aspect of lung cancer screening is addressing the moral obligation. As part of the Hippocratic oath, physicians promise to first “do no harm.”[11] The dilemma is that if lung cancer screening is beneficial but physicians do not use it, they are denying patients effective care. However, if lung cancer screening is not effective, then patients may be harmed from overdiagnosis, increased testing, invasive

testing or procedures, and the anxiety of a potential cancer diagnosis. Debates from mammography and prostate cancer screening may provide additional insight for lung cancer screening, especially regarding the problem of overdiagnosis (see “Randomized Trials” in this Discussion).[12]

CT as Part of a Screening Program

Lung cancer screening with CT should be part of a program of care and should not be performed in isolation as a free-standing test. Given the high percentage of false-positive results and the downstream management that ensues for many patients, the risks and benefits of lung cancer screening should be discussed with the individual before a screening LDCT scan is performed. It is recommended that institutions performing lung cancer screening use a multidisciplinary approach that may include specialties such as chest radiology, pulmonary medicine, and thoracic surgery.[13] Management of downstream testing and follow-up of small nodules are imperative and may require the establishment of administrative processes to ensure adequate follow-up. Guidelines from ACCP (American College of Chest Physicians) and ASCO (American Society of Clinical Oncology) state that only centers with considerable expertise in lung cancer screening should do LDCT.[14]

Randomized Trials

Disease-specific mortality (number of cancer deaths relative to number of individuals screened) is considered the ultimate test of screening effectiveness and the only test that is without bias.[15] Randomized controlled screening trials are essential for determining whether cancer screening decreases disease-specific mortality. Nonrandomized trials are subject to biases that may cause an apparent increase in survival (eg, lead-time bias, length-time bias) (http://www.cancer.gov/newscenter/qa/2002/nlstqaQA).

If lung cancer is detected through screening before symptoms occur, then the lead time in diagnosis equals the length of time between screening detection and when the diagnosis otherwise would have occurred, either as a result of symptoms or other imaging. Even if early treatment had no benefit, the survival of the screened person is increased simply by the addition of the lead time. Length-time bias refers to the tendency of the screening test to detect cancers that take longer to become symptomatic, possibly because they are slower-growing and perhaps indolent cancers. Survival (the number of individuals who are alive after detection and treatment of disease relative to the number of individuals diagnosed with the disease) has often been reported but is subject to these biases.[7] For further discussion of randomized and nonrandomized screening trials, see “Benefits of Lung Cancer Screening” in this Discussion.

In the 1960s and 1970s, several randomized trials assessed whether chest radiographs could improve lung cancer survival. Many of these studies were flawed in their design or power, and all were negative.[16] A recent phase III randomized trial (The Prostate, Lung, Colorectal, and Ovarian [PLCO]) reported that annual screening with chest radiographs is not useful for lung cancer screening in low-risk patients.[17] More recently, studies have focused on the more sensitive modality of helical LDCT–based lung cancer screening studies (see “Benefits of Lung Cancer Screening” in this Discussion). However, analyses of some lung cancer screening studies using LDCT scans suggest that overdiagnosis (ie, diagnosis of “cancer” that would never be life-threatening) and false-positive screening tests are significant concerns.[18-20] Thus, although LDCT scanning may be a better screening test for lung cancer,

it also has limitations (see “Benefits of Lung Cancer Screening” and “Risks of Lung Cancer Screening” in this Discussion).

Multiple ongoing randomized trials are assessing LDCT screening for lung cancer among high-risk groups, including 1) the National Lung Screening Trial (NLST), sponsored by the NCI[7]; and 2) the Dutch Belgian randomized lung cancer screening trial (NELSON).[21-24] In November 2010, preliminary results from the NLST suggested that LDCT screening decreases disease-specific mortality. The published results show that LDCT decreased the relative risk of death from lung cancer by 20% (95% CI, 6.8–26.7; *P* = .004) when compared with chest radiography alone.[8] Although the NLST also reported a significant decrease in all cause mortality of 7%, the apparent decrease is not significant after lung cancer mortality is subtracted.

Other Lung Cancer Screening Guidelines

The NCCN was the first major organization to develop lung cancer screening guidelines using LDCT based on the NLST data.[25] The recent report from the International Association for the Study of Lung Cancer (IASLC) supports the NCCN guidelines by emphasizing the need for guidelines, a multidisciplinary team approach, and integrated smoking cessation programs.[13]

Recently, the ACCP and ASCO also recommended lung cancer screening for patients who meet the criteria of the NLST (ie, high-risk smokers and former smokers age 55-74 years with a 30 pack-year smoking history); this recommendation has also been approved by the American Thoracic Society.[14] The ACCP and ASCO guidelines also emphasize the need for a multidisciplinary team approach and smoking cessation.

Other organizations have developed interim guidelines for lung cancer screening (eg, American Cancer Society [ACS], American Lung Association [ALA]).

High-Risk Individuals

An essential goal of any lung cancer screening protocol is to identify the populations that are at a high risk for developing the disease. Although smoking tobacco is a well-established risk factor for lung cancer, other environmental and genetic factors also seem to increase risk. This section reviews the currently known risk factors for the development of lung cancer to identify high-risk populations that should be targeted for screening. Note that high-risk individuals who are recommended for screening do not have any symptoms suggestive of lung cancer (eg, cough, chest pain, weight loss).

Tobacco Smoke

Active Tobacco Use

Tobacco smoking is a major modifiable risk factor in the development of lung cancer and accounts for 85% of all lung cancer–related deaths.[1,6] The causal relationship between tobacco smoking and lung cancer was first reported in 1939. Since then, the risk of developing lung cancer from smoking tobacco has been firmly established. Tobacco smoke contains more than 7000 compounds, and more than 50 of these are known carcinogens that increase the risk of cancerous mutations at the cellular level, especially among individuals with a genetic predisposition.[26-28] The FDA has recently defined a list of 93 chemicals that are considered harmful or potentially harmful constituents (HPHCs) in tobacco products or tobacco smoke.

A dose–response relationship exists between smoking tobacco and the risk of developing lung cancer; however, there is no risk-free level of

tobacco exposure (http://cancercontrol.cancer.gov/tcrb/monographs/7/m7_6.pdf). The relative risk (RR) for lung cancer is approximately 20-fold higher[1,29] for smokers than for nonsmokers. Cessation of tobacco smoking decreases the risk of lung cancer.[30-32] However, even former smokers have a higher risk of lung cancer compared with never-smokers (http://cancercontrol.cancer.gov/tcrb/monographs/8/index.html). As a result, current or past history of tobacco smoking is considered a risk factor for the development of lung cancer, irrespective of the magnitude of exposure and the time since smoking cessation. In the algorithm, individuals (aged 55–74 years) with a 30 or more pack-year history of smoking tobacco are selected as the highest-risk group for lung cancer and are recommended for screening (category 1) based on criteria for entry into the NLST.[7,8] *Pack-years* of smoking history is defined as the number of packs of cigarettes smoked every day multiplied by the number of years of smoking. Individuals with a 30 pack-year smoking history who quit smoking less than 15 years ago are still in this highest-risk group.

Exposure to Second-Hand Smoke

The relationship between lung cancer and exposure to second-hand smoke (also known as *environmental tobacco smoke*, *passive smoke*, and *involuntary smoke*) was first suggested in epidemiologic studies published in 1981.[33] Since then, several studies and pooled RR estimates suggest that second-hand smoke causally increases the risk for lung cancer among nonsmokers (http://www.surgeongeneral.gov/library/secondhandsmoke/factsheets/factsheet6.html).[34] However, the NCCN Lung Cancer Screening Panel does not consider second-hand smoke to be an independent risk factor, because the association is either weak or variable. Thus, second-hand smoke does not confer a great enough risk for exposed individuals to be considered for lung cancer screening in these guidelines.

A pooled analysis of 37 published studies found an estimated RR of 1.24 (95% CI, 1.13–1.36) for adult nonsmokers who live with a smoker.[35] A pooled estimate from 25 studies found an RR of 1.22 (95% CI, 1.13–1.33) for lung cancer risk from exposure to second-hand smoke at the workplace.[34] The pooled estimate for 6 studies suggests a dose–response relationship between number of years of second-hand smoke exposure and lung cancer risk.[34] The data are inconsistent for second-hand smoke exposure during childhood and subsequent lung cancer risk in adulthood. For childhood tobacco smoke exposure, pooled RR estimates for the development of lung cancer were 0.93 (95% CI, 0.81–1.07) for studies conducted in the United States, 0.81 (95% CI, 0.71–0.92) for studies conducted in European countries, and 1.59 (95% CI, 1.18–2.15) for studies conducted in Asian countries.[34]

Occupational Exposure

Approximately 150 agents are classified as known or probable human carcinogens (IARC 2002). Agents that are identified specifically as carcinogens targeting the lungs include arsenic, chromium, asbestos, nickel, cadmium, beryllium, silica, diesel fumes, coal smoke, and soot.[36-41] The calculated mean RR for development of lung cancer is 1.59 for individuals in the United States who have a known occupational exposure to these agents.[38,41] Among those who are exposed to these carcinogens, smokers have a greater risk for lung cancer than nonsmokers.[42]

Residential Radon Exposure

Radon (a gaseous decay product of uranium-238 and radium-226) has been implicated in the development of lung cancer.[43] The risk of lung cancer from occupational exposure among uranium miners is well established.[44] However, the risk associated with residential radon is uncertain. A meta-analysis in 1997 of 8 studies yielded an estimated RR

of 1.14 (95% CI, 1.0–1.3).[45] However, a 2005 meta-analysis of 13 studies (using individual patient data) reported a linear relationship between the amount of radon detected in a home and the risk of developing lung cancer.[46] Among those exposed to radon, smokers have a greater risk for lung cancer than nonsmokers.[46]

Cancer History

Evidence shows an increased risk of new primary cancers among patients who survive lung cancer, lymphomas, cancers of the head and neck, or smoking-related cancers (eg, esophageal cancer). Patients who survive small cell lung cancer have a 3.5-fold increase in the risk for developing a new primary cancer (predominantly NSCLC).[47]

The risk for subsequent lung cancers is increased in patients who continue to smoke and who have been previously treated with either chest irradiation or alkylating agents. Patients previously treated with chest irradiation have a 13-fold increase in risk for developing new primary lung cancer, and those previously treated with alkylating agents have an estimated RR of 9.4. In patients previously treated for Hodgkin's lymphoma, the RR for new primary lung cancer is 4.2 if previously treated with alkylating agents, and 5.9 if previously treated with 5 Gy or more of radiation therapy.[48]

In patients with head and neck cancers, subsequent new primary lung cancer may occur synchronously or metachronously. New primary tumors are seen in approximately 9% of patients. Most of these tend to be squamous cell cancers and a third of them occur in the lung. In patients with laryngeal or hypopharyngeal cancer, the lung is the most common site of second primary cancers.[49] However, data do not suggest that previous treatment for head and neck cancers increases the risk of subsequent new primary lung cancer independent of tobacco exposure.[50,51] Evidence suggests that patients who are successfully treated (ie, cured) for an initial smoking-related lung cancer and who stop smoking will have a decreased risk of a subsequent smoking-related cancer compared with those who continue smoking.[52]

Family History of Lung Cancer

Several studies have suggested an increased risk for lung cancer among first-degree relatives of patients with lung cancer, even after adjustment for age, gender, and smoking habits.[53,54] A meta-analysis of 28 case-control studies and 17 observational cohort studies showed an RR of 1.8 (95% CI, 1.6–2.0) for individuals with a sibling/parents or a first-degree relative with lung cancer.[55] The risk is greater in individuals with multiple affected family members or who had a cancer diagnosis at a young age.

Although no high-penetrance inherited syndrome has been described for lung cancer (either small cell lung cancer or NSCLC), several groups have identified genetic loci that may be associated with an increased risk of developing lung cancer. The Genetic Epidemiology of Lung Cancer Consortium conducted a genome-wide linkage analysis of 52 families who had several first-degree relatives with lung cancer. Linkage disequilibrium was shown on chromosome 6, localizing a susceptibility locus influencing lung cancer risk to 6q23-25.[56] Subsequently, 3 groups performed genome-wide association studies in patients with lung cancer and matched controls. They found a locus at 15q24-25 associated with an increased risk of lung cancer, nicotine dependence, and peripheral artery disease.[57-59] It was noted that subunits of the nicotinic acetylcholine receptor genes are localized to this area (CHRNA5, CHRNA3, and CHRNB4). Other investigators recently found that a variant at 15q24/25 is associated with spirometric bronchial obstruction and emphysema as assessed with CT.[60] Patients with classic familial cancer susceptibility syndromes (such as retinoblastoma, Li-Fraumeni

syndrome) have a substantially increased risk for lung cancer if they also smoke tobacco.[61-63]

History of Lung Disease in the Patient

Chronic Obstructive Pulmonary Disease

A history of chronic obstructive pulmonary disease (COPD) is associated with lung cancer risk,[64-70] and this association may be largely caused by smoking. Yang et al.[71] found that COPD accounts for 12% of lung cancer cases among heavy smokers. However, even after statistical adjustment, evidence suggests that the association between COPD and lung cancer may not be entirely caused by smoking.[72] For example, 1) family history of chronic bronchitis and emphysema is associated with increased risk of lung cancer, and 2) COPD is associated with lung cancer among never-smokers.[71-73] Yang et al.[71] found that COPD accounts for 10% of lung cancer cases among never-smokers. Koshiol et al.[72] found that when they restricted their analyses to adenocarcinoma (which is more common among nonsmokers, particularly women), COPD was still associated with an increased risk of lung cancer.

Pulmonary Fibrosis

Patients with diffuse pulmonary fibrosis seem to be at a higher risk for lung cancer even after age, gender, and a history of smoking are taken into consideration (RR, 8.25; 95% CI, 4.7–11.48).[74,75] Among patients with a history of exposure to asbestos, those who develop interstitial fibrosis are at a higher risk of developing lung cancer than those without fibrosis.[76]

Hormone Replacement Therapy

Whether use of hormone replacement therapy (HRT) affects the risk of lung cancer in women is currently unclear. More than 20 studies have been published and the results have been inconsistent. Most of the currently available information comes from case-control and cohort studies. Cumulatively, these studies are variable; they have found associations ranging from an increased risk of lung cancer, no effect on risk, and a protective effect against lung cancer risk. However, in a large randomized controlled study,[77] no increase in the incidence of lung cancer was found among postmenopausal women treated with estrogen plus progestin HRT, but deaths from lung cancer (especially NSCLC) were higher among patients receiving HRT.

Selection of High-Risk Individuals for Screening

Well-known risk factors exist for the development of lung cancer, especially smoking tobacco. Results from the recently concluded NLST support screening select individuals who are at high risk for lung cancer.[8] The NCCN Lung Cancer Screening Panel recommends that high-risk individuals should be screened; however, moderate- and low-risk individuals should not be screened currently. Patients are selected for the different risk categories using the NLST inclusion criteria, nonrandomized studies, and/or observational studies. However, screening with LDCT should only be considered for select high-risk individuals if they are potential candidates for definitive treatment (ie, curative intent therapy).

Based on the available data, the NCCN Lung Cancer Screening Panel recommends using the following criteria to determine whether individuals are at high, moderate, or low risk for lung cancer.

High-Risk Individuals

The NCCN Lung Cancer Screening Panel recommends lung cancer screening using helical LDCT for individuals with the following high-risk factors:

•Age 55 to 74 years; 30 or more pack-year history of smoking tobacco; and, if former smoker, have quit within 15 years (category 1).[7,8] Some high-risk individuals in the NLST also had COPD and other risk factors. This is a category 1 recommendation because these individuals are selected based on the NLST inclusion criteria.[7,8] An NCCN category 1 recommendation is based on high-level evidence (ie, randomized controlled trial) and uniform consensus among panel members. Annual screening is recommended for these high-risk individuals for 2 years (category 1) based on the NLST.[8] Annual screening can be considered until the patient is no longer eligible for definitive treatment. However, uncertainty exists about the appropriate duration of screening and the age at which screening is no longer appropriate.

•Age 50 years or older, 20 or more pack-year history of smoking tobacco, and one additional risk factor (category 2B). This is a category 2B recommendation because these individuals are selected based on lower level evidence (eg, nonrandomized studies, observational data, and ongoing randomized trials)[24,78-83] and because some panel members would not recommend LDCT for these individuals These additional risk factors were previously described and include cancer history, lung disease history, family history of lung cancer, radon exposure, and occupational exposure.[38,46,48,55,72] Note that the NCCN Lung Cancer Screening Panel does not currently believe that exposure to second-hand smoke is an independent risk factor, because the data are either weak or variable (see “Exposure to Second-Hand Smoke” in this Discussion).

In the second high-risk group of patients in the NCCN guidelines (ie, ≥ 50 years old, one additional risk factor), the age range for LDCT was extended (ie, ≥ 50 years and > 74 years) for several reasons. NCCN panel members feel that these individuals are also at high risk for lung cancer based on the NLST and data from other studies as elucidated below. The NCCN panel members felt that the NLST inclusion criteria do identify high-risk individuals with category 1 evidence but that limitation to the NLST criteria alone is arbitrary and naïve because high risk is not limited only to a narrow age range and because other well-known risk factors for lung cancer should also be considered. Others share this opinion.[84] Two ongoing phase III randomized trials are screening patients 50-55 years old. The NELSON screening trial is assessing LDCT in individuals 50-75 years old.[21,24] The Danish Lung Cancer Screening Trial (DLCST) is screening individuals 50-70 years old.[85] A modeling study suggests that it is reasonable to screen select high-risk patients age 50-55 years.[86] However, LDCT has not been shown yet to decrease mortality in patients with these risk factors; therefore, some panel members would not recommend screening for these individuals.

It is uncertain what the age cutoff should be, where screening is no longer appropriate.[14] The NCCN guidelines acknowledge that select high-risk individuals older than 74 years are also eligible for LDCT. At diagnosis of lung cancer, the median age of patients is 70 years (http://seer.cancer.gov/statfacts/html/lungb.html). Approximately 52% of lung cancer is diagnosed in patients age 55-74 years; however, about 28% of lung cancer is diagnosed in older patients age 75-84 years. Several cohort studies have assessed LDCT using an extended age range (ranging from 50-85 years old).[87-89] Thus, annual LDCT seems reasonable for select high-risk patients older than 74 years who are eligible for definitive treatment, generally defined as curative intent therapy (eg, surgery, chemoradiation, stereotactic body radiation therapy [SBRT]).

The NCCN guidelines recommend considering annual LDCT until individuals are no longer eligible for definitive treatment. However, uncertainty exists about the appropriate duration of screening.[14] After the 3 rounds of LDCT in the NLST, new cases (367 cases) of lung cancer were frequently diagnosed during the 3.5 years of follow-up (median of 6.5 years).[8,90] The NLST data show that lung cancer

continues to occur in high-risk patients over time. In addition, the incidence of lung cancer and the death rate from lung cancer did not change during the 7 years of the NLST.[91] Thus, the NLST data support annual LDCT for at least 2 years but do not define a time limit on efficacy.

Individuals with reduced smoking history (ie, 20 or more pack-year) are recommended for LDCT in the NCCN guidelines if they also have at least one other independent risk factor for lung cancer besides smoking (eg, family history, occupational exposure).[38,55,80] These additional risk factors were selected because they are recognized as being associated with lung cancer; thus, they have been incorporated into different risk models that have been developed for predicting lung cancer.[78-80,82] Although the NCCN guidelines recognize that the use of these risk factors is based on lower level evidence, others also feel it is reasonable to screen individuals with these risk factors.[91]

Moderate-Risk Individuals

NCCN defines moderate-risk individuals as those aged 50 years or older and with a 20 or more pack-year history of smoking tobacco or second-hand smoke exposure but no additional lung cancer risk factors. The NCCN Lung Cancer Screening Panel does not recommend lung cancer screening for these moderate-risk individuals. This is a category 2A recommendation based on nonrandomized studies and observational data.[14,86]

Low-Risk Individuals

NCCN defines low-risk individuals as those younger than 50 years and/or with a smoking history of fewer than 20 pack-years. The NCCN Lung Cancer Screening Panel does not recommend lung cancer screening for these low-risk individuals. This is a category 2A recommendation based on nonrandomized studies and observational data.[14,86]

Accuracy of LDCT Protocols and Imaging Modalities

As shown in the NCCN algorithm, LDCT is recommended for detecting noncalcified nodules that may be suspicious for lung cancer depending on their type and size (eg, solid, part solid, and ground glass nodules). The prevalence of malignancy has been reported as follows: ground glass opacities (GGOs; 59%), mixed GGOs and solid (48%), and solid (11%). GGOs have the highest incidence of malignancy; 75% of persistent GGOs are cancer.[92] However, the GGOs are mainly adenocarcinoma in situ (AIS) or minimally invasive adenocarcinoma (MIA), formerly known as *bronchioloalveolar carcinomas* (BAC), which have a 5-year disease-free survival of 100% if completely resected.[92,93] Solid and part-solid nodules are more likely to be invasive and faster-growing cancers, factors that are reflected in the increased suspicion and follow-up of these nodules.[19,94,95] GGOs, ground glass nodules (GGNs), and nonsolid nodules are terms that are often used synonymously.[96] Part-solid (also known as semi-solid or subsolid) nodules include 1) GGOs, and 2) a mixed nodule containing GGOs and a solid component.[19,96]

Helical multidetector CT (MDCT) of the chest has made it possible to detect very small lung nodules, both benign and malignant. The ability to acquire thinner slices, the use of maximum intensity projection (MIP) or volume-rendered (VR) images, and computer-aided diagnosis (CAD) software have increased the sensitivity of small-nodule detection.[97-106] The use of thinner images has also improved the characterization of small lung nodules.[107]

For lung cancer screening, LDCT without intravenous contrast is currently recommended (instead of standard-dose CT) to decrease the

dose of radiation. Although there is no strict definition of LDCT of the chest, it is usually considered to be approximately 10% to 30% of standard-dose CT. In most cases, LDCT has been shown to be as accurate as standard-dose CT for detecting solid pulmonary nodules, although nodule detection with LDCT may be limited in larger patients.[108,109] However, LDCT seems to be less sensitive for detecting very low-density nonsolid nodules or GGOs.[110] Decreasing the radiation dose does not significantly affect the measurement of nodule size when using 1-mm thick slices.[111] These low-dose scans require radiologists to assess images that are much noisier than they are currently used to seeing. Studies suggest that some variation occurs in interpretation of LDCT scans among radiologists.[112,113]

Recent LDCT lung cancer screening studies using MDCT have reported that lung cancer mortality is decreased when compared with unscreened cohorts or those receiving chest radiographs.[8,114] However, studies using multidetector LDCT screening for lung cancer in high-risk patients have applied various different protocol algorithms for detection and follow-up of pulmonary nodules/lesions (http://www.ielcap.org/professionals/protocols.html).[7,85,87,115-119] These protocols have been based on the positive relationships among 1) nodule size and/or nodule consistency/density and likelihood of malignancy; 2) nodule size and tumor stage; and 3) tumor stage and survival. They also take into account the average growth rate of lung cancer (ie, doubling time).[83,120-126] Most of these protocols recommend dynamic contrast-enhanced CT and/or PET/CT be considered for nodules that are at least 7 to 10 mm, because these technologies have been shown to increase specificity for malignancy.[127-131] If lung nodules have higher uptake on PET compared to surrounding lung parenchyma (ie, hypermetabolism in the lung nodules), then the nodules are suspicious for lung cancer, regardless of the standardized uptake value (SUV) analysis.[129,132] In the workup of pulmonary nodules detected with CT in a high-risk lung cancer screening population, the roles of contrast-enhanced CT and PET/CT are still in evolution.[133,134]

Optimally, these lung cancer screening methods will increase detection of early stage lung cancer and decrease false-positive results, unnecessary invasive procedures, radiation exposure, and cost. In at least one medical center, improvement in CT equipment and change in screening protocol have been shown to increase early lung cancer detection, decrease the surgery rate, and improve cancer-specific survival.[135] Strict adherence to a screening protocol may also significantly reduce unnecessary biopsies.[136]

Currently, the most accurate protocol for lung cancer detection using LDCT is difficult to determine because of differing patient populations, methodologies, lengths of follow-up, and statistical analyses among lung cancer screening studies. Recent LDCT screening programs (with multiple years of follow-up) report that 65% to 85% of their detected lung cancers are stage I.[118,131] The I-ELCAP (International Early Lung Cancer Action Program) and NLST are the largest recent series examining lung cancer detection using LDCT in high-risk patients (see “Benefits of Lung Cancer Screening” in this Discussion).[7,83] Differences in screening algorithms or recommended diagnostic pathways between these studies are summarized in Table 1 and at http://www.acrin.org/TabID/145/Default.aspx; http://www.ielcap.org/professionals/protocols.html).[7,83]

In 2005, the Fleischner Society published guidelines for the management of small pulmonary nodules detected on LDCT scans.[94] Most radiologists in the United States are aware of these guidelines and/or work in a practice that uses them.[137] However, these recommendations do not specifically address the management of

part-solid or nonsolid pulmonary nodules. Although understanding of the histology and behavior of nonsolid and part-solid nodules has changed recently, interim guidelines for the assessment and management of subsolid nodules were recently proposed.[19]

Because of the familiarity and/or acceptance of the Fleischner Society guidelines among radiologists, pulmonologists, and thoracic surgeons, these same principles have been incorporated into the NCCN recommendations for lung cancer screening. The NCCN recommendations in the algorithm are an adaptation of the Fleischner Society guidelines, proposed guidelines for subsolid nodules by Godoy, NLST data, and the I-ELCAP protocol guidelines (http://www.ielcap.org/professionals/docs/ielcap.pdf).[19,94] The currently proposed NCCN recommendations are less aggressive (ie, less-frequent LDCT) than the I-ELCAP protocol for the workup of baseline and new solid and part-solid nodules 6 mm or smaller. However, the NCCN recommendations are slightly different (ie, consider PET/CT) from the I-ELCAP protocol (see Table 1) in the evaluation of solid and part-solid nodules larger than 8 mm, because the NCCN Guidelines recommend considering short-term assessment with PET/CT (to increase nodule specificity) rather than longer-term assessment with LDCT.

The NCCN definition of *nodule growth:* 1) for nodules 15 mm or smaller: an increase in mean diameter of 2 mm or more in any nodule or in the solid portion of a part-solid nodule when compared with the baseline scan, or 2) for nodules 15 mm or more: an increase of 15% in mean diameter when compared with the baseline scan. *Mean diameter* is the mean of the longest diameter of the nodule and its perpendicular diameter. This definition of nodule growth is based on intraobserver and interobserver variability when measuring small pulmonary nodules, and on the minimum change in diameter that can be reliably detected using conventional methods (excluding volumetric analysis software).[138] This definition of nodule growth is simplified compared with the formula used by I-ELCAP (see Table 1), which requires nodule growth of 1.5 to 3.0 mm in mean diameter for nodules 3 to 15 mm, depending on their diameter. The NCCN definition of nodule growth should also result in fewer false-positive diagnoses compared with the NLST suggested definition of nodule growth (≥ 10% increase in nodule diameter).[8]

Currently, the NCCN recommendations do not take into consideration other possibly relevant nodule features, such as proximity to the pleura or fissure.[139-141] The topics of nodule volumetric analysis and/or calculations of tumor doubling time have not been addressed either.[84] The NELSON trial is using volumetric analysis, which has decreased the false-positive rate to 64%; the NLST had a false-positive rate of 96%.[13,21,115] Only 2.6% of individuals had a positive initial test result in the NELSON trial compared with 24% in the NLST. In some cases, it may be appropriate to perform standard-dose CT with or without intravenous contrast for follow-up or further evaluation of lung or mediastinal abnormalities detected on screening LDCT. Note that if endobronchial nodules are suspected, then LDCT is recommended after 1 month. The technician should ask the patient to cough vigorously, then the LDCT should be immediately done.

The recommended LDCT acquisition parameters in these NCCN Guidelines (see Table 2) are similar to many of the recent and ongoing lung cancer screening studies using low-dose MDCT. Use of MIP, VR, and/or CAD software is highly recommended in addition to evaluation of conventional axial images for increased sensitivity of small nodule detection. A detector collimation of 1.5 mm or less is necessary for optimal use of these 3-dimensional applications. For accurate nodule volumetric analysis, some radiologists feel that a detector collimation of 1 mm or less is needed. Measurement and evaluation of small nodules

are more accurate and consistent on 1-mm thick images compared with 5-mm images.[107] There may be a similar but less-pronounced benefit in evaluating nodules on 1-mm reconstructed images after detecting them on 2.5- to 3.0-mm thick slices. Because slice thickness, reconstruction algorithms, and postprocessing filters affect nodule size measurement, the same technical parameters should be used for each screening LDCT. Ultra-low-dose chest CT currently produces lower sensitivity for nodule detection, especially in larger patients.[109] However, new LDCT technologies may soon make it possible to significantly decrease the radiation dose without compromising nodule detection and evaluation.[142-145]

Benefits of Lung Cancer Screening

This section summarizes current information about the possible or projected benefits of screening for lung cancer using helical LDCT scans, including 1) decreased lung cancer mortality, or improvement in other oncologic outcomes, 2) quality-of life benefits from screening and early detection (compared with standard clinical detection), and 3) detection of disease, other than lung cancer, that requires treatment.[9,14,91]

Oncology Outcomes

After a clinical diagnosis of NSCLC, survival is directly related to stage at diagnosis.[5] Although patients with earliest-stage disease (IA) may have a 5-year survival rate of approximately 75% with surgery, the outcomes quickly decrease with increasing stage (eg, 5-year survival is 71% for stage IB; 58% for IIA; 49% for IIB; and < 25% for stages III and IV).[146] Note that staging for NSCLC was recently revised in January 2010 (see the NCCN Guidelines for NSCLC).[147]

Although it is intuitively appealing to conclude that earlier detection of disease will improve outcome, screen-detected lung cancers may have a different natural history from that of clinically detected cancers[148,149] and an apparent improvement in survival from early detection itself (lead-time bias). Pathology results of resected lung cancers detected through prior screening trials suggest that screening increases the detection of indolent cancer. However, randomized trial data from the NLST show that LDCT screening decreases lung cancer mortality.[8]

Nonrandomized Trials

Of the single-armed screening studies (ie, nonrandomized), the I-ELCAP study is the largest. It included 31,567 high-risk patients from around the world, all of whom were to be screened with baseline and annual LDCT scans analyzed centrally in New York.[83] In the I-ELCAP study, Henschke et al.[83] reported that a high percentage of stage I cancers (85%) were detected using LDCT, with an estimated 92% actuarial 10-year survival rate for stage I cancers resected within 1 month of diagnosis (62% of all cancers detected). The authors noted that 3 participants with clinical stage I cancer—who opted not to undergo treatment—all died within 5 years, findings similar to those of published medical literature examining the natural history of stage I NSCLC.[150,151] They concluded that annual helical LDCT screening can detect lung cancer that is curable. Important caveats about I-ELCAP include that it was not randomized, the median follow-up time was only 40 months, and fewer than 20% of the subjects were observed for more than 5 years. Given the limited follow-up, the 10-year survival estimates may have been overstated.

A study by Bach et al.[152] raised concern that LDCT screening may lead to overdiagnosis of indolent cases without substantially decreasing the number of advanced cases or the overall attributable deaths from lung cancer. However, although overdiagnosis did occur with LDCT in the

NLST, the magnitude was not large when compared with radiographic screening (83 vs. 17 stage IA BAC, also known as AIS or MIA).[8,90,93] Data from the ELCAP suggest that baseline CT scans find more indolent cancers, and subsequent annual scans find more rapidly growing cancers.[153]

Another recent analysis of 7995 participants in the NY-ELCAP single-arm screening trial (the precursor to the I-ELCAP) compared the observed death rate from lung cancer among ELCAP subjects with that seen in participants in large cancer prevention cohort studies who were not undergoing prescribed lung cancer screening with LDCT scans.[114] The analysis was adjusted for age, gender, and smoking status, and suggested a significant reduction in deaths from lung cancer of 40% to 60% among the screened cohort.

Randomized Trials

To address the concerns of bias and overdiagnosis from single-arm screening (ie, nonrandomized) studies, the NCI launched the NLST in 2002.[7] The NLST was a prospective, randomized lung cancer screening trial comparing annual LDCT scan versus annual chest radiograph for 2 years; this trial was designed to have 90% power to detect a 21% decrease in the primary end point of lung cancer–specific mortality in the screened group. The investigators enrolled 53,454 high-risk participants aged 55 to 74 years who had smoking history of at least 30 pack-years. If subjects were no longer smoking tobacco, they had to have quit within the previous 15 years. All screening examinations were completed by mid-2007, and the study mandated a Data Safety Monitoring Board (DSMB) that met twice annually to evaluate follow-up information. In October 2010, the DSMB concluded that sufficient information was available to assess the primary outcome of the study. In November 2010, a NCI press release was issued about the NLST findings. The NLST results are published and showed that annual LDCT decreased the relative risk of death from lung cancer by 20% (http://www.cancer.gov/newscenter/pressreleases/2011/NLSTprimaryNEJM).[8]

The NLST participants were similar to a United States census population of heavy smokers in terms of gender, but the NLST population was generally younger, better educated, and less likely to be current smokers. Subjects in both the LDCT screening and chest radiograph screening arms were very compliant (> 90%) with their designated screening tests. The screening tests were deemed positive if there was a finding that was suspicious for lung cancer (ie, suspicious nodule).[7] Overall, 24% of the LDCT scans and 7% of the chest radiographs performed were positive screens, an imbalance that was expected based on prior data. In each of the 3 rounds of screening, positive LDCT scan screens were determined to be actual lung cancer cases (ie, true-positive) 4%, 2%, and 5% of the time, compared with 6%, 4%, and 7% for positive chest radiographs.

Based on the published NLST results, 356 participants died of lung cancer in the LDCT arm and 443 participants died of lung cancer in the chest radiograph arm.[8] Thus, annual LDCT decreased the relative risk of death by 20%.These results are impressive, and the NLST represents the first randomized study showing an improvement in either disease-specific or overall mortality when using a lung cancer screening program. The NLST results indicate that to prevent one death from lung cancer, 320 high-risk individuals must be screened with LDCT. The NLST results will likely change medical practice in the United States. Results of the NELSON trial may confirm the NLST findings in a separate cohort. Further analysis of the NLST, including comparative effectiveness modeling, is underway.

The 20% reduction in mortality from LDCT screening (compared with chest radiograph) may actually be greater in clinical practice, because chest radiographs are not currently recommended for lung cancer screening as standard practice (by either the American Thoracic Society or the American College of Chest Physicians).[154] In addition, if annual lung screening is continued for more than 2 years, this increased screening may yield mortality reductions of more than 20% (which was reported by the NLST after annual lung screening for only 2 years). Recent findings suggest that showing the benefit of breast cancer screening requires follow-up of at least 20 years.[155]

Quality of Life

The NLST assessed quality of life among participants at the time of each annual screening study, but these results are not yet available. Possible quality-of-life benefits from early lung cancer detection (as opposed to detection at the time of clinical symptoms) include 1) reduction in disease-related morbidity, 2) reduction in treatment-related morbidity, 3) alterations in health affecting lifestyles, and 4) reduction in anxiety and psychological burden.

Reduction in Disease-Related Morbidity

It is a reasonable assumption that the disease-related symptom burden would be decreased in patients whose lung cancer is detected early (via screening) compared with late (via clinical presentation). Most patients whose lung cancer is detected early are asymptomatic, and detection is often either incidental or part of a screening protocol.[7] Historically, most patients with lung cancer presented with symptoms of the disease (including cough, dyspnea, hemoptysis, pain, weight loss, and cachexia), and thus their lung cancer was detected clinically. An important analysis of the NLST quality-of-life data will be to assess the 2 cohorts for differences in the types of symptoms experienced at the time of lung cancer diagnosis to see if screening truly can decrease the lung cancer symptom burden. In addition, lung cancer screening may identify other clinical conditions unrelated to lung cancer that require follow-up (eg, coronary artery calcification, COPD, other cancers); presumably, treatment of these other conditions will decrease the overall disease burden.[95,156-158]

Reduction in Treatment-Related Morbidity

Patients with early stage lung cancer primarily are treated surgically, sometimes with adjuvant chemotherapy, whereas those with more advanced disease are treated with a combination of chemotherapy and radiation, or chemotherapy alone (see the NCCN Guidelines for NSCLC).[159,160] Patients with early stage lung cancer who undergo an R0 resection have increased survival compared with those with more advanced disease who undergo definitive chemoradiation therapy.[161] However, few data have been published comparing the treatment burden of surgery versus chemoradiation therapy. It seems reasonable to assume that a patient with stage I lung cancer requiring a lobectomy alone (or SBRT, also known as stereotactic ablative radiotherapy [SABR]) probably has less treatment-related morbidity than a patient with stage III lung cancer requiring combined-modality therapy (ie, chemotherapy, radiation, and a possible lung resection).[162,163] However, this has not been shown.

The NLST found that 40% of the cancers detected in the CT-screening group were stage IA, 12% were stage IIIB, and 22% were stage IV.[8] Conversely, 21% of the cancers detected in the chest radiograph group were stage IA, 13% were stage IIIB, and 36% were stage IV. These results suggest that LDCT screening decreases the number of cases of advanced lung cancer, and therefore may decrease treatment-related morbidity. Lung cancer screening may reduce the number of patients who require pneumonectomy for treatment of lung cancer, which will reduce treatment-related morbidity and mortality. Several series have

shown that pneumonectomy is performed in only 1% of cases of lung cancer diagnosed in CT screening programs, in contrast to the 20% to 30% rate of pneumonectomy in symptom-detected cases.[164-167]

Patients with early stage lung cancer may be eligible for treatment that would not be appropriate for those with advanced stage disease. Video assisted thorascopic surgery (VATS) is an option for patients with early stage NSCLC (eg, those who may not tolerate or may refuse an open lobectomy).[168-171] VATS lobectomy is associated with less morbidity than open lobectomy. Recent data suggest that SBRT is also a reasonable option for patients with early stage lung cancer who are not eligible for surgery.[162,172,173]

Alterations in Health That Affect Lifestyles

The process of lung cancer screening itself has been suggested to increase smoking cessation rates. Conversely, it has also been suggested that negative results on a lung cancer screening test may provide a false sense of security to smokers and result in higher smoking rates.[174] Neither hypothesis has been supported by any substantial evidence. A nonrandomized screening study reported that smoking cessation rates were higher when more follow-up LDCT scans were ordered for abnormal findings, regardless of ultimate diagnosis of cancer, suggesting that patients became “scared” into quitting.[175] In a controlled study, however, smoking abstinence rates were similarly higher than expected in both screened and unscreened arms. This result suggests that the positive effect on smoking cessation was likely unrelated to the screening test results and may reflect a higher desire to be healthy among volunteers participating in screening clinical trials.[176]

Smokers, including those undergoing lung cancer screening, should always be encouraged to quit smoking tobacco (http://www.smokefree.gov/).[177] Likewise, former smokers should be encouraged to remain abstinent. Lung cancer screening is not a substitute for smoking cessation. Programs using behavioral counseling combined with medications that promote smoking cessation (approved by the FDA) can be very useful in helping individuals to quit smoking (see *Quick Reference Guide for Clinicians: Treating Tobacco Use and Dependence*).

Reduction in Anxiety and Psychological Burden

As with mammogram screening for breast cancer, whether lung cancer screening causes anxiety or improves overall quality of life has been a topic of discussion. The randomized NELSON screening study recently published health-related quality-of-life data from 733 participants. In the short term, recipients of an indeterminate result from the LDCT scan experienced increased distress, whereas relief was experienced after a negative baseline screening examination.[178] After 2 years of follow-up, data from the NELSON trial suggest that lung screening did not adversely affect quality of life.[179] However, further longitudinal studies are needed to determine the long-term effect. Patients’ attitudes toward risk in their life (risk perception) also greatly affect their anxiety when undertaking cancer screening examinations.[180] Little definitive research is available to support or refute effects on quality of life from lung cancer screening.

Risks of Lung Cancer Screening

Lung cancer screening with LDCT has inherent risks and benefits.[14,90,181] These risks must be understood to determine whether screening is beneficial. The possible or projected risks of screening for lung cancer using LDCT scans include 1) false-positive results, leading to unnecessary testing, unnecessary invasive procedures (including surgery), increased cost, and decreased quality of life because of mental anguish; 2) false-negative results, which may delay or prevent diagnosis and treatment because of a false sense of good health; 3)

futile detection of small aggressive tumors (which have already metastasized, preventing meaningful survival benefit from screening); 4) futile detection of indolent disease (ie, overdiagnosis), which would never have harmed the patient who subsequently undergoes unnecessary therapy; 5) indeterminate results, leading to additional testing; 6) radiation exposure; and 7) physical complications from diagnostic workup. Patients with several comorbid conditions may be at greater risk than those with few or none.

False-Positive Results

Lung cancer screening studies (which have included only high-risk populations) have found a high rate of noncalcified nodules larger than 4 mm on LDCT screening, with false-positive rates ranging from 10% to 43%.[88,166,182-185] In the NLST, the false-positive rate was 96.4% for the CT screening group.[8] The cumulative risk of a false-positive result was 33% for a person undergoing lung cancer screening with 2 sequential annual examinations.[182] Thus, LDCT had a high rate of sensitivity but a low rate of specificity in the NLST. These false-positive results in the NLST were probably due to benign intrapulmonary lymph nodes and noncalcified granulomas.[8] Recent data from the NELSON trial show that using volumetric analysis decreases the false-positive rate.[21,115]

False-positive and indeterminate results require follow-up, which may include surveillance with chest LDCT scans, percutaneous needle biopsy, or even surgical biopsy.[95] Each of these procedures has its own risks and potential harms.[186] Approximately 7% of individuals with a false-positive result will undergo an invasive procedure (typically bronchoscopy).[182] However, in the NLST, the rate of major complications after an invasive procedure was very low (only 0.06%) after workup for a false-positive result in the CT screening group.[8]

The NCCN lung cancer screening protocol may avoid much of the most-invasive follow-up for noncalcified nodules that are detected on baseline screening with LDCT. The NCCN protocol uses the NLST and I-ELCAP protocols/recommendations (see Table 1) and the Fleischner Society guidelines and is based on expert opinion from the NCCN panel members.[187] However, even repeat chest LDCT scanning is associated with risk for 1) increased radiation exposure; 2) increased cost of follow-up scans and clinic visits; and 3) ongoing anxiety to the individual, who must wait for the results of repeat chest LDCT scans. Bach et al.[152] also provide insight into the potential harms of LDCT screening, which results in a 3-fold increase in lung cancer diagnosis and a 10-fold increase in lung cancer surgery; this represents substantial psychological and physical burdens. Although the I-ELCAP investigators reported a surgical mortality rate of only 0.5% (when surgery is performed by board certified thoracic surgeons at cancer centers), the average surgical mortality rate for major lung surgery across the United States is 5%, and the frequency of serious complications is greater than 20%.[188] These potential harms associated with thoracic surgery[188-190] mandate that the effectiveness of LDCT screening be accurately assessed. Methods of decreasing potential harms with thoracic surgery include using treatment with less morbidity (eg, sublobar resection, VATS lobectomy), using minimally invasive diagnostics (endobronchial ultrasound and navigational bronchoscopy), and utilizing experienced, dedicated, multidisciplinary teams to minimize unnecessary testing and procedures and the morbidity of those procedures.

False-Negative Results

Sone et al.[191] published 2 reports on lung cancers missed at screening.[192,193] Of the 88 lung cancers diagnosed, 32 were missed on 38 LDCT scans; 23 from detection errors (with a mean size of 9.8 mm)

and 16 from interpretation errors (with a mean size of 15.9 mm). Detection errors included 1) subtle lesions (91%) appearing as GGOs; and 2) lesions (83%) that were overlapped with, obscured by, or similar in appearance to normal structures (such as blood vessels). Interpretation errors (87%) were seen in patients who had underlying lung disease, such as tuberculosis, emphysema, or fibrosis.

The second report revealed that 84% of missed cancers in that database were subsequently detected using an automated lung nodule detection method. The CAD method involved the use of gray-level thresholding techniques to identify 3-dimensionally contiguous structures with the lungs, which were possible nodule candidates. The problem is that CAD systems are not universally deployed, and the success of detecting disease can vary greatly among radiologists. The variability and success of CAD and volumetric analysis systems may also affect the success of screening trials. Recently, a database of lung nodules on CT scans was published to provide an imaging resource for radiologists, which may help to decrease false-negative and false-positive results.[194]

Although these issues are partly being addressed through NCI-sponsored programs (such as the RIDER and PAR 08-225 programs), the range in variability at various centers, particularly outside of academic institutions, may lead to significant differences in results compared with those published from clinical trials. False-negative results from a screening test may provide an individual patient with a false sense of security, causing a patient to perhaps ignore symptoms that may have otherwise led to more evaluation.

Futile Detection of Small Aggressive Tumors

Early detection using lung cancer screening may not be beneficial if a small tumor is very aggressive and has already metastasized, with a loss of opportunity for effective treatment. Studies show that a 5-mm lung cancer has undergone approximately 20 doublings yielding 10^8 cells, whereas patient death typically occurs with a tumor burden of 10^{12} cells.[195] Even small tumors may have already metastasized. Studies have also shown that metastases can occur at the time of angiogenesis, when lesions are approximately 1 to 2 mm.[196] Human tumors grown in nude mouse models can shed 3 to 6 million cells per gram of tissue every 24 hours,[197] providing the potential for early metastasis.

However, the NLST trial results show that lung cancer screening is effective in select high-risk patients.[8] The data from this trial show that detecting and treating lung lesions lead to a reduction in lung cancer–specific mortality. Therefore, the likelihood of futile therapy in patients with screen-detected tumors is much less, albeit not zero. However, because the natural history of lung cancer is heterogeneous and not completely predictable or linear,[198] the potential remains for futile treatment in patients with an aggressive tumor that is already incurable at the time of screening diagnosis.

Futile Detection of Indolent Disease

Although lung cancer specialists generally have a strong opinion of the uniform fatality of untreated lung cancer, recent studies of some low-grade lung cancers (ie, BAC) show a potential for prolonged survival in some patients with NSCLC, even without therapy.[199,200] Note that a new lung adenocarcinoma classification has recommended that the term *BAC* should not be used anymore. Newly defined entities of AIS and MIA, which are likely to present as ground glass nodules (GGNs), should have 100% 5-year disease-free survival rate if completely resected.[93,199] A greater percentage of the lepidic pattern (formerly BAC pattern), which corresponds with the ground glass component in a part-solid nodule, is correlated with a more favorable prognosis.[93,199,200]

Furthermore, experience in lung cancer screening has raised the question of increased identification of indolent tumors in the screened population.[152,201] These indolent tumors may not cause symptoms or cancer mortality; therefore, patients do not benefit from screening and subsequent workup and treatment. A percentage of these patients will be exposed to the risk, morbidity, and mortality of surgical resection that, in retrospect, will not increase their life expectancy. As the newly defined entities of AIS and MIA (formerly BAC) with excellent survival have been separated from overtly invasive adenocarcinomas, the potential exists to learn how to minimize surgical intervention for pure GGNs through CT screening studies and long-term follow-up.[93]

Bach et al.[152] found an increase in the number of patients with lung cancer detected through screening, yet no evidence of a decline in the number of deaths from lung cancer. Their nonrandomized study raised concern that LDCT screening may lead to overdiagnosis of indolent cases and to the morbidity of treatment, without a survival benefit. However, the recent randomized NLST found that LDCT does decrease lung cancer mortality.[8]

Quality of Life

The effect of lung cancer screening on the quality of life (see “Benefits of Lung Cancer Screening” in this Discussion) is not fully known. A study by van den Bergh et al.[202] found no measured adverse effects, although approximately half of the participants reported discomfort while waiting for the results. However, others have reported significant personal and physical quality-of-life issues from screening tests (http://health.usnews.com/usnews/health/articles/030519/19diagnosis.htm). Several studies (including the NLST and NELSON trial) will be measuring quality-of-life issues.[178,179] Recent data from the NELSON trial suggest that lung screening did not adversely affect quality of life.[179] False-positive and indeterminate results may decrease quality of life because of mental anguish and additional testing.

During the NLST, 3 rounds of LDCT screening were done (ie, baseline, year 1, year 2) and then individuals were followed for an additional 3.5 years. Lung cancer was diagnosed between annual screens in some patients (ie, interval cancers); lung cancer was also diagnosed during follow-up.[8] Thus, individuals should be cautioned that LDCT may not identify all lung cancers or prevent death from lung cancer.[8] In addition, they should be informed that a positive test result does not mean they have lung cancer because many false-positive results occur with LDCT.

Unnecessary Testing

Any lung cancer screening program will result in additional testing. In a report by Croswell et al.[203] (from the Prostate, Lung, Colorectal, and Ovarian [PLCO] trial), the cumulative risk of having one false-positive result was 60% for men and 49% for women. The cumulative risk of undergoing an invasive diagnostic procedure prompted by the false-positive test was 29% for men and 22% for women. The NLST was a carefully supervised, randomized, controlled trial. In a less-controlled environment, the rate of additive studies may be higher. Sistrom et al.[204] reviewed the recommendations for additional imaging in more than 5.9 million radiology reports; they reported additional imaging of 35.8% for chest LDCT. The issue of incidental findings on screening examinations is problematic, and some organizations are attempting to address the issue, but regional and physician variations remain.[205]

Radiation Exposure With LDCT

Current MDCT scanners provide a significantly enhanced capability for detecting small nodules through allowing thinner slice images. Using low-dose techniques, the mean effective radiation dose is 1.5 mSv (SD, 0.5 mSv) compared with an average of 7 mSv for conventional CT

(www.cancer.gov/newscenter/qa/2002/nlstqaQA).[8,9,206] However, the radiation dose of LDCT is 10 times that of chest radiography.

There may be even more reason to be concerned about use of chest LDCT scans for lung cancer screening, because these individuals, who are already at high risk for lung cancer, may experience adverse effects from increased radiation exposure. In fact, the effects of repeated exposure to radiation at regular intervals are not known. Brenner[207] estimated a 1.8% increase in lung cancer cases if 50% of all current and former smokers in the United States between 50 and 75 years of age were to undergo annual LDCT scans for lung cancer screening. However, lower doses of radiation are now used for LDCT scans and these lower doses may be less dangerous.[208] The risk of radiation exposure over long periods will have to be considered when screening guidelines are developed, especially when recommending how frequently the scans should be performed.

Increased Cost

Many are concerned about the effect of lung cancer screening on medical resources, including the cost of LDCT screening and additional testing. The cost of a LDCT scan is about $527 (in 2011 US dollars).[209] The number of high-risk individuals eligible for lung cancer screening is approximately 7 million (using NLST data).[8] Depending on the screening rate (50% or 75%), the annual cost in the United States is estimated to be about $1.3-2 billion,[209] although this may change when the NLST cost-effectiveness analysis is published. About $12.1 billion is spent each year on lung cancer care in the United States.[209]

Helical LDCT screening will lead to false-positive results, detection of indeterminate nodules, and detection of potential disease other than lung cancer. In the NLST, although 24.2% of the LDCT scans were positive, most of these were false-positive (96.4%).[8] Follow-up for "positive" nodules typically involves further imaging.[8] Assuming a 50% screening rate, a conservative estimate of the annual cost of working up false-positive nodules is about $800 million (3.5 million × 23% × $1000). This estimate does not include costs of workup for other potential abnormalities detected during screening, such as cardiac and upper abdominal pathology. Of individuals with a false-positive result, approximately 7% will undergo an invasive procedure (typically bronchoscopy).[182]

Limiting screening to only high-risk patients not only helps avoid unnecessary risks in individuals with a lower risk of cancer but also is important for decreasing the costs of the screening program. "Pre-screening" based on age, smoking history, appropriate medical history, family history, and occupational history is important to determine which patients are at high risk.

Lack of well-defined guidelines can lead to overuse of screening. Excessive screening and/or interpretations of studies by unskilled individuals may occur without strict guidelines (as with mammography). Other factors, such as the interval at which screening should be performed, will also affect calculations of cost. In the recent screening studies using helical LDCT, 23% of the ELCAP and 69% of the 1999 Mayo Clinic study had at least one indeterminate nodule. Depending on the size and characteristics of the indeterminate nodule, further evaluation may include serial follow-up LDCT, dynamic contrast-enhanced nodule densitometry, PET, or biopsy. False-positive results also lead to additional unnecessary testing and increased cost. The financial burden, potential complications from invasive procedures, and psychological effect of investigating these indeterminate and false-positive lesions are not fully understood.

Lung screening also leads to detection of disease other than lung cancer, such as infection; coronary artery calcification; COPD; and renal, adrenal, and liver lesions.[95,156-158,210,211] Although detection of other diseases may frequently provide a clinical benefit to the patient, certainly costs will be further increased with additional testing and treatment. It is important to rule out infection; however, antimicrobials are not indicated for chronic lesions. Inappropriate use of antimicrobials may cause adverse side effects and will increase cost. Incidental lesions may also be detected, which may require further testing (eg, intrapulmonary lymph nodes, noncalcified granulomas, thyroid incidentalomas, upper abdominal lesions).[8]

Cost-Benefit and Cost-Effectiveness Analyses

The cost-effectiveness of lung cancer screening is also important to consider. LDCT imaging is more expensive than many other screening programs, and therefore it is important to validate the effectiveness of screening.[212] The cost of a LDCT scan is estimated to be $527 (in 2011 US dollars).[209] Note that cost-benefit analysis provides dollar values for the outcomes, whereas cost-effectiveness analysis provides cost per health outcome (eg, cost per life-year gained) (http://www.cdc.gov/owcd/eet/CostEffect2/fixed/1.html).

Only a small number of preliminary cost–benefit analyses have been done for lung cancer screening, and many are based on modeled predictive systems because randomized clinical trials have been completed only recently.[213] These cost analyses have some limitations because they used simulation modeling.[214-217] The Mahadevia study concluded that false-positive results are a major obstacle to LDCT screening and may prevent it from being cost-effective.[216] However, recent data from the NELSON trial show that volumetric analysis decreases the false-positive rate with LDCT.[21] Wisnivesky et al.[218] have argued that LDCT lung cancer screening is potentially highly cost effective and that the cost-effectiveness ratios are not different from those of other screening programs. A recent analysis by McMahon et al.[214] emphasizes that cost-effectiveness of LDCT is linked to smoking cessation rates. The NLST cost-effectiveness evaluation has not been published yet but will be extremely beneficial in understanding this issue.[209]

A fundamental flaw with cost–benefit analyses for lung cancer screening is that the true benefit of screening requires more years of follow-up and more years of screening to realize the full potential; therefore, this crucial factor has been arbitrarily assigned or assumed in prior analyses.[155] The types of assumptions made can significantly affect the conclusions of the analysis. Furthermore, many cost–benefit analyses do not adequately represent the detrimental effects of false-positive test results on screening. For a person undergoing lung cancer screening with 2 sequential annual examinations, the cumulative risk of a false-positive test result was 33%.[182] The economic effect of false-positive cancer screening results has been estimated to be at least $1000 per incident.[219]

The original ELCAP study constructed a decision analysis model from its data.[218] The investigators documented that diagnostic procedure costs and hospital/physician costs in the first year after the diagnosis of lung cancer proportionally increased with increasing stage. Because they detected primarily early stage cancers, they estimated that a baseline screening LDCT scan could increase survival by 0.1 year at an incremental cost of approximately $230 (this study was published in 2003). The incremental cost per life-year gained ratio is also very sensitive to the fraction of the patients screened and found to have early stage disease; the higher the percentage of patients found with early stage disease, the lower the incremental cost ratio.[215] The

emerging NSLT data must be carefully examined to ascertain the proportion of patients diagnosed with early stage disease, their comparative mortality and morbidity, and the associated costs. Additional studies to examine other cohorts at risk will also be helpful in future cost-effectiveness analysis models.

Summary

Lung cancer screening with LDCT is a complex and controversial topic, with inherent risks and benefits. Results from the large, prospective, randomized NLST showed that screening with LDCT decreased the relative risk of death from lung cancer by 20% in a select group of high-risk individuals.[8] The NLST results indicate that to prevent one death from lung cancer, 320 high-risk individuals must be screened with LDCT. However, the NLST findings have not been replicated yet in a separate cohort. Further analysis of the NLST is underway, including comparative effectiveness modeling. The cost-effectiveness and true benefit-to-risk ratio for lung cancer screening still must be determined. At some point, an acceptable level of risk will have to be deemed appropriate for the benefits of screening.

The NCCN Lung Cancer Screening Panel recommends helical LDCT screening for select individuals at high risk for lung cancer based on the NLST results, nonrandomized studies, and observational data. These guidelines discuss in detail the criteria for determining which patients are at high risk, and the algorithm provides recommendations for evaluating and following-up nodules detected on LDCT screening (eg, solid and part-solid nodules).

Smokers should always be advised to quit smoking tobacco (http://www.smokefree.gov/). Programs using behavioral counseling combined with medications that promote smoking cessation (approved by the FDA) can be very useful (see *Treating Tobacco Use and Dependence: Quick Reference Guide for Clinicians*; http://www.surgeongeneral.gov/tobacco/tobaqrg.htm). Former smokers should be encouraged to remain abstinent.

When considering lung cancer screening, it is important to have a full understanding of all risks and benefits related to screening with LDCT. As policies for implementing lung screening programs are designed, a focus on multidisciplinary programs (incorporating chest radiology, pulmonary medicine, and thoracic surgery) will be helpful to optimize decision-making and minimize interventions for patients with benign lung disease.

Table 1 Comparison of the I-ELCAP and NLST Lung Screening Protocols

Definition of Positive Nodule*	**I-ELCAP**	**NLST†**
Baseline	Solid and PS nodule ≥ 5mm‡	Nodule ≥ 4mm
	NS nodule ≥ 8mm‡	
Annual	New solid or PS nodule	Same as Baseline
	New NS nodule ≥ 8mm‡	
Recommendations for Positive Nodule		
Baseline	LDCT in 3 mo, then resume annual LDCT if stable. Consider PET if solid component >10mm. Biopsy if PET positive; annual LDCT if PET negative. If nodule ≥ 15mm, treat with antibiotics and LDCT at 1 mo, or biopsy. LDCT in 1 mo for solid endobronchial nodule.	Solid or PS nodule 4-10mm, then LDCT 3-6 mo. NS nodule 4-10mm, then LDCT 6-12 mo. If growth but nodule < 7mm, then LDCT in 3-6 mo. If growth and nodule ≥ 7mm, then follow recommendations of nodules > 10mm. Any nodule > 10mm consider biopsy, CECT, PET/CT; or LDCT in 3-6 mo if low suspicion.
Annual	Annual LDCT if NS nodule < 8mm. LDCT in 6 mo if new solid/PS nodule. Antibiotics and 1 mo LDCT if solid/PS nodule ≥ 5mm or NS nodule ≥ 8mm, then LDCT at 3 mo if nodule stable.	Same as Baseline
Definition of Nodule Growth	≥ 50% increase in mean diameter if nodule <5mm	≥ 10% increase in nodule diameter
	≥ 30% increase in mean diameter if nodule 5-9mm	
	≥ 20% increase in mean diameter if nodule >10mm	

CECT = contrast-enhanced CT; CT = computed tomography; I-ELCAP = International Early Lung Cancer Action Program; LDCT = low-dose CT;

NLST = National Lung Screening Trial; NS = nonsolid; PET = positron-emission tomography; PS = part solid.

I-ELCAP protocol. Available at (http://www.ielcap.org/professionals/protocols.html). Accessed May 17, 2012.

NLST protocol. Available at (http://www.acrin.org/TabID/145/Default.aspx). Accessed May 17, 2012.

*Requiring imaging or workup in addition to annual LDCT. †Guidelines rather than a strict study regimen. ‡Mean diameter of nodule.

Table 2 Low-Dose Computed Tomography Acquisition, Storage, Interpretation, and Nodule Reporting

Acquisition	**Small Patient (BMI ≤ 30)**	**Large Patient (BMI > 30)**
Total radiation exposure	≤ 3 mSv	≤ 5 mSv
kVp	100-120	120
mAs	≤ 40	≤ 60
	All Patients	
Gantry rotation speed	≤ 0.5	
Detector collimation	≤ 1.5 mm	
Slice width	≤ 3 mm; ≤ 1.5 mm preferred	
Slice interval	≤ slice width; 50% overlap preferred for 3D and CAD applications	
Scan acquisition time	≤ 10 seconds (single breath hold)	
Breathing	Maximum inspiration	
Contrast	No oral or intravenous contrast	
CT scanner detectors	≥ 16	
Storage	All acquired images, including thin sections; MIPs and CAD renderings if used	
Interpretation Tools		
Platform	Computer workstation review	
Image type	Standard and MIP images	
Comparison studies	Comparison with prior chest CT images (not reports) is essential to evaluate change in size, morphology, and density of nodules; review of serial chest CT exams is important to detect slow growth	

BMI = body mass index; CAD = computer aided diagnostics; CT = computed tomography; MIP = maximum intensity projection.

Continued on the next page.

Table 2 *Continued*

Low-Dose Computed Tomography Acquisition, Storage, Interpretation, and Nodule Reporting

Nodule Parameters	All Patients
Size	Largest mean diameter on a single image*
Density	Solid, ground glass, or mixed†
Calcification	Present/absent; if present: solid, central vs eccentric, concentric rings, popcorn, stippled, amorphous
Fat	Report if present
Shape	Round/ovoid, triangular
Margin	Smooth, lobulated, spiculated
Lung location	By lobe of the lung, preferably by segment, and if subpleural
Location in dataset	Specify series and image number for future comparison
Temporal comparison	If unchanged, include the longest duration of no change as directly viewed by the interpreter on the images (not by report); if changed, report current and prior size

BMI = body mass index; CAD = computer-aided diagnosis; CT = computed tomography; MIP = maximum intensity projection.

*Mean of the longest diameter of the nodule and its perpendicular diameter, when compared to the baseline scan.

†Mixed, otherwise referred to as part solid.

References

1. The Health Consequences of Smoking: A Report of the Surgeon General (ed 2010/07/30). Atlanta: US Department of Health and Human Services; 2004.

2. Thun MJ, Henley SJ, Burns D, et al. Lung cancer death rates in lifelong nonsmokers. J Natl Cancer Inst 2006;98:691-699. Available at: http://www.ncbi.nlm.nih.gov/pubmed/16705123.

3. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin 2011;61:69-90. Available at: http://www.ncbi.nlm.nih.gov/pubmed/21296855.

4. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012;62:10-29. Available at: http://www.ncbi.nlm.nih.gov/pubmed/22237781.

5. Goldstraw P, Crowley J, Chansky K, et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol 2007;2:706-714. Available at: http://www.ncbi.nlm.nih.gov/pubmed/17762336.

6. Jemal A, Thun MJ, Ries LA, et al. Annual report to the nation on the status of cancer, 1975-2005, featuring trends in lung cancer, tobacco use, and tobacco control. J Natl Cancer Inst 2008;100:1672-1694. Available at: http://www.ncbi.nlm.nih.gov/pubmed/19033571.

7. Aberle DR, Berg CD, Black WC, et al. The National Lung Screening Trial: overview and study design. Radiology 2011;258:243-253. Available at: http://www.ncbi.nlm.nih.gov/pubmed/21045183.

8. Aberle DR, Adams AM, Berg CD, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med 2011;365:395-409. Available at: http://www.ncbi.nlm.nih.gov/pubmed/21714641

9. Kramer BS, Berg CD, Aberle DR, Prorok PC. Lung cancer screening with low-dose helical CT: results from the National Lung Screening Trial (NLST). J Med Screen 2011;18:109-111. Available at: http://www.ncbi.nlm.nih.gov/pubmed/22045816.

10. Midthun DE. Screening for lung cancer. Clin Chest Med 2011;32:659-668. Available at: http://www.ncbi.nlm.nih.gov/pubmed/22054878.

11. Lee CI, Forman HP. CT screening for lung cancer: implications on social responsibility. AJR Am J Roentgenol 2007;188:297-298. Available at: http://www.ncbi.nlm.nih.gov/pubmed/17242233.

12. Welch HG, Black WC. Overdiagnosis in cancer. J Natl Cancer Inst 2010;102:605-613. Available at: http://www.ncbi.nlm.nih.gov/pubmed/20413742.

13. Field JK, Smith RA, Aberle DR, et al. International Association for the Study of Lung Cancer Computed Tomography Screening Workshop 2011 report. J Thorac Oncol 2012;7:10-19. Available at: http://www.ncbi.nlm.nih.gov/pubmed/22173661.

14. Bach PB, Mirkin JN, Oliver TK, et al. Benefits and harms of CT screening for lung cancer: a systematic review. JAMA 2012:1-12. Available at: http://www.ncbi.nlm.nih.gov/pubmed/22610500.

15. Hulka BS. Cancer screening. Degrees of proof and practical application. Cancer 1988;62:1776-1780. Available at: http://www.ncbi.nlm.nih.gov/pubmed/3048638.

16. Humphrey LL, Johnson M, Teutsch S. Lung cancer screening: An update for the U.S. Preventive Services Task Force [Internet] (ed 2010/08/20); 2004.

17. Oken MM, Hocking WG, Kvale PA, et al. Screening by chest radiograph and lung cancer mortality: the Prostate, Lung, Colorectal, and Ovarian (PLCO) randomized trial. JAMA 2011;306:1865-1873. Available at: http://www.ncbi.nlm.nih.gov/pubmed/22031728.

18. Reich JM. A critical appraisal of overdiagnosis: estimates of its magnitude and implications for lung cancer screening. Thorax 2008;63:377-383. Available at: http://www.ncbi.nlm.nih.gov/pubmed/18364449.

19. Godoy MCB, Naidich DP. Subsolid pulmonary nodules and the spectrum of peripheral adenocarcinomas of the lung: recommended interim guidelines for assessment and management. Radiology 2009;253:606-622. Available at: http://www.ncbi.nlm.nih.gov/pubmed/19952025.

20. Black WC. Computed tomography screening for lung cancer: review of screening principles and update on current status. Cancer 2007;110:2370-2384. Available at: http://www.ncbi.nlm.nih.gov/pubmed/17941031.

21. Ru Zhao Y, Xie X, de Koning HJ, et al. NELSON lung cancer screening study. Cancer Imaging 2011;11 Spec No A:S79-84. Available at: http://www.ncbi.nlm.nih.gov/pubmed/22185865.

22. Xu DM, Gietema H, de Koning H, et al. Nodule management protocol of the NELSON randomised lung cancer screening trial. Lung Cancer 2006;54:177-184. Available at: http://www.ncbi.nlm.nih.gov/pubmed/16989922.

23. Nair A, Hansell DM. European and North American lung cancer screening experience and implications for pulmonary nodule management. Eur Radiol 2011;21:2445-2454. Available at: http://www.ncbi.nlm.nih.gov/pubmed/21830100.

24. van Iersel CA, de Koning HJ, Draisma G, et al. Risk-based selection from the general population in a screening trial: selection criteria, recruitment and power for the Dutch-Belgian randomised lung cancer multi-slice CT screening trial (NELSON). Int J Cancer 2007;120:868-874. Available at: http://www.ncbi.nlm.nih.gov/pubmed/17131307.

25. Wood DE, Eapen GA, Ettinger DS, et al. Lung cancer screening. J Natl Compr Canc Netw 2012;10:240-265. Available at: http://www.ncbi.nlm.nih.gov/pubmed/22308518.

26. Hecht SS. Tobacco smoke carcinogens and lung cancer. J Natl Cancer Inst 1999;91:1194-1210. Available at: http://www.ncbi.nlm.nih.gov/pubmed/10413421.

27. Secretan B, Straif K, Baan R, et al. A review of human carcinogens--Part E: tobacco, areca nut, alcohol, coal smoke, and salted fish. Lancet Oncol 2009;10:1033-1034. Available at: http://www.ncbi.nlm.nih.gov/pubmed/19891056.

28. Sakoda LC, Loomis MM, Doherty JA, et al. Germ line variation in nucleotide excision repair genes and lung cancer risk in smokers. Int J Mol Epidemiol Genet 2012;3:1-17. Available at: http://www.ncbi.nlm.nih.gov/pubmed/22493747.

29. Smoking-attributable mortality, years of potential life lost, and productivity losses--United States, 2000-2004. MMWR Morb Mortal Wkly Rep 2008;57:1226-1228. Available at: http://www.ncbi.nlm.nih.gov/pubmed/19008791.

30. Doll R, Peto R, Boreham J, Sutherland I. Mortality in relation to smoking: 50 years' observations on male British doctors. BMJ 2004;328:1519. Available at: http://www.ncbi.nlm.nih.gov/pubmed/15213107.

31. Moolgavkar SH, Holford TR, Levy DT, et al. Impact of reduced tobacco smoking on lung cancer mortality in the United States during 1975-2000. J Natl Cancer Inst 2012;104:541-548. Available at: http://www.ncbi.nlm.nih.gov/pubmed/22423009.

32. Peto R, Darby S, Deo H, et al. Smoking, smoking cessation, and lung cancer in the UK since 1950: combination of national statistics with two case-control studies. BMJ 2000;321:323-329. Available at: http://www.ncbi.nlm.nih.gov/pubmed/10926586.

33. Garfinkel L. Time trends in lung cancer mortality among nonsmokers and a note on passive smoking. J Natl Cancer Inst 1981;66:1061-1066. Available at: http://www.ncbi.nlm.nih.gov/pubmed/6941041.

34. The Health Consequences of Involuntary Exposure to Tobacco Smoke: A Report of the Surgeon General (ed 2010/07/30). Atlanta; 2006.

35. Hackshaw AK, Law MR, Wald NJ. The accumulated evidence on lung cancer and environmental tobacco smoke. BMJ 1997;315:980-988. Available at: http://www.ncbi.nlm.nih.gov/pubmed/9365295.

36. Straif K, Benbrahim-Tallaa L, Baan R, et al. A review of human carcinogens--part C: metals, arsenic, dusts, and fibres. Lancet Oncol 2009;10:453-454. Available at: http://www.ncbi.nlm.nih.gov/pubmed/19418618.

37. Silverman DT, Samanic CM, Lubin JH, et al. The diesel exhaust in miners study: a nested case-control study of lung cancer and diesel exhaust. J Natl Cancer Inst 2012;104:855-868. Available at: http://www.ncbi.nlm.nih.gov/pubmed/22393209.

38. Driscoll T, Nelson DI, Steenland K, et al. The global burden of disease due to occupational carcinogens. Am J Ind Med 2005;48:419-431. Available at: http://www.ncbi.nlm.nih.gov/pubmed/16299703.

39. Nelson DI, Concha-Barrientos M, Driscoll T, et al. The global burden of selected occupational diseases and injury risks: Methodology and summary. Am J Ind Med 2005;48:400-418. Available at: http://www.ncbi.nlm.nih.gov/pubmed/16299700.

40. Nurminen M, Karjalainen A. Epidemiologic estimate of the proportion of fatalities related to occupational factors in Finland. Scand J Work Environ Health 2001;27:161-213. Available at: http://www.ncbi.nlm.nih.gov/pubmed/11444413.

41. Steenland K, Loomis D, Shy C, Simonsen N. Review of occupational lung carcinogens. Am J Ind Med 1996;29:474-490. Available at: http://www.ncbi.nlm.nih.gov/pubmed/8732921.

42. Reid A, de Klerk NH, Ambrosini GL, et al. The risk of lung cancer with increasing time since ceasing exposure to asbestos and quitting smoking. Occup Environ Med 2006;63:509-512. Available at: http://www.ncbi.nlm.nih.gov/pubmed/16849527.

43. El Ghissassi F, Baan R, Straif K, et al. A review of human carcinogens--part D: radiation. Lancet Oncol 2009;10:751-752. Available at: http://www.ncbi.nlm.nih.gov/pubmed/19655431.

44. Leuraud K, Schnelzer M, Tomasek L, et al. Radon, smoking and lung cancer risk: results of a joint analysis of three European case-control studies among uranium miners. Radiat Res 2011;176:375-387. Available at: http://www.ncbi.nlm.nih.gov/pubmed/21714633.

45. Lubin JH, Boice JD, Jr. Lung cancer risk from residential radon: meta-analysis of eight epidemiologic studies. J Natl Cancer Inst 1997;89:49-57. Available at: http://www.ncbi.nlm.nih.gov/pubmed/8978406.

46. Darby S, Hill D, Auvinen A, et al. Radon in homes and risk of lung cancer: collaborative analysis of individual data from 13 European case-control studies. BMJ 2005;330:223. Available at: http://www.ncbi.nlm.nih.gov/pubmed/15613366.

47. Tucker MA, Murray N, Shaw EG, et al. Second primary cancers related to smoking and treatment of small-cell lung cancer. Lung Cancer Working Cadre. J Natl Cancer Inst 1997;89:1782-1788. Available at: http://www.ncbi.nlm.nih.gov/pubmed/9392619.

48. Travis LB, Gospodarowicz M, Curtis RE, et al. Lung cancer following chemotherapy and radiotherapy for Hodgkin's disease. J Natl Cancer Inst 2002;94:182-192. Available at: http://www.ncbi.nlm.nih.gov/pubmed/11830608.

49. Morris LG, Sikora AG, Patel SG, et al. Second primary cancers after an index head and neck cancer: subsite-specific trends in the era of human papillomavirus-associated oropharyngeal cancer. J Clin Oncol 2011;29:739-746. Available at: http://www.ncbi.nlm.nih.gov/pubmed/21189382.

50. Jones AS, Morar P, Phillips DE, et al. Second primary tumors in patients with head and neck squamous cell carcinoma. Cancer 1995;75:1343-1353. Available at: http://www.ncbi.nlm.nih.gov/pubmed/7882285.

51. Atabek U, Mohit-Tabatabai MA, Raina S, et al. Lung cancer in patients with head and neck cancer. Incidence and long-term survival. Am J Surg 1987;154:434-438. Available at: http://www.ncbi.nlm.nih.gov/pubmed/3661848.

52. Richardson GE, Tucker MA, Venzon DJ, et al. Smoking cessation after successful treatment of small-cell lung cancer is associated with fewer smoking-related second primary cancers. Ann Intern Med 1993;119:383-390. Available at: http://www.ncbi.nlm.nih.gov/pubmed/8393311.

53. Jonsson S, Thorsteinsdottir U, Gudbjartsson DF, et al. Familial risk of lung carcinoma in the Icelandic population. JAMA 2004;292:2977-2983. Available at: http://www.ncbi.nlm.nih.gov/pubmed/15613665.

54. Li X, Hemminki K. Familial multiple primary lung cancers: a population-based analysis from Sweden. Lung Cancer 2005;47:301-307. Available at: http://www.ncbi.nlm.nih.gov/pubmed/15713513.

55. Matakidou A, Eisen T, Houlston RS. Systematic review of the relationship between family history and lung cancer risk. Br J Cancer 2005;93:825-833. Available at: http://www.ncbi.nlm.nih.gov/pubmed/16160696.

56. Bailey-Wilson JE, Amos CI, Pinney SM, et al. A major lung cancer susceptibility locus maps to chromosome 6q23-25. Am J Hum Genet 2004;75:460-474. Available at: http://www.ncbi.nlm.nih.gov/pubmed/15272417.

57. Thorgeirsson TE, Geller F, Sulem P, et al. A variant associated with nicotine dependence, lung cancer and peripheral arterial disease. Nature 2008;452:638-642. Available at: http://www.ncbi.nlm.nih.gov/pubmed/18385739.

58. Hung RJ, McKay JD, Gaborieau V, et al. A susceptibility locus for lung cancer maps to nicotinic acetylcholine receptor subunit genes on 15q25. Nature 2008;452:633-637. Available at: http://www.ncbi.nlm.nih.gov/pubmed/18385738.

59. Amos CI, Wu X, Broderick P, et al. Genome-wide association scan of tag SNPs identifies a susceptibility locus for lung cancer at 15q25.1. Nat Genet 2008;40:616-622. Available at: http://www.ncbi.nlm.nih.gov/pubmed/18385676.

60. Lambrechts D, Buysschaert I, Zanen P, et al. The 15q24/25 susceptibility variant for lung cancer and chronic obstructive pulmonary disease is associated with emphysema. Am J Respir Crit Care Med 2010;181:486-493. Available at: http://www.ncbi.nlm.nih.gov/pubmed/20007924.

61. Hwang SJ, Cheng LS, Lozano G, et al. Lung cancer risk in germline p53 mutation carriers: association between an inherited cancer predisposition, cigarette smoking, and cancer risk. Hum Genet 2003;113:238-243. Available at: http://www.ncbi.nlm.nih.gov/pubmed/12802680.

62. Sanders BM, Jay M, Draper GJ, Roberts EM. Non-ocular cancer in relatives of retinoblastoma patients. Br J Cancer 1989;60:358-365. Available at: http://www.ncbi.nlm.nih.gov/pubmed/2789942.

63. Fletcher O, Easton D, Anderson K, et al. Lifetime risks of common cancers among retinoblastoma survivors. J Natl Cancer Inst 2004;96:357-363. Available at: http://www.ncbi.nlm.nih.gov/pubmed/14996857.

64. Mayne ST, Buenconsejo J, Janerich DT. Previous lung disease and risk of lung cancer among men and women nonsmokers. Am J Epidemiol 1999;149:13-20. Available at: http://www.ncbi.nlm.nih.gov/pubmed/9883789.

65. Samet JM, Humble CG, Pathak DR. Personal and family history of respiratory disease and lung cancer risk. Am Rev Respir Dis 1986;134:466-470. Available at: http://www.ncbi.nlm.nih.gov/pubmed/3752703.

66. Alavanja MC, Brownson RC, Boice JD, Jr., Hock E. Preexisting lung disease and lung cancer among nonsmoking women. Am J Epidemiol 1992;136:623-632. Available at: http://www.ncbi.nlm.nih.gov/pubmed/1442729.

67. Wu-Williams AH, Dai XD, Blot W, et al. Lung cancer among women in north-east China. Br J Cancer 1990;62:982-987. Available at: http://www.ncbi.nlm.nih.gov/pubmed/2257230.

68. Gao YT, Blot WJ, Zheng W, et al. Lung cancer among Chinese women. Int J Cancer 1987;40:604-609. Available at: http://www.ncbi.nlm.nih.gov/pubmed/2824385.

69. Brenner AV, Wang Z, Kleinerman RA, et al. Previous pulmonary diseases and risk of lung cancer in Gansu Province, China. Int J Epidemiol 2001;30:118-124. Available at: http://www.ncbi.nlm.nih.gov/pubmed/11171871.

70. Skillrud DM, Offord KP, Miller RD. Higher risk of lung cancer in chronic obstructive pulmonary disease. A prospective, matched, controlled study. Ann Intern Med 1986;105:503-507. Available at: http://www.ncbi.nlm.nih.gov/pubmed/3752756.

71. Yang P, Sun Z, Krowka MJ, et al. Alpha1-antitrypsin deficiency carriers, tobacco smoke, chronic obstructive pulmonary disease, and lung cancer risk. Arch Intern Med 2008;168:1097-1103. Available at: http://www.ncbi.nlm.nih.gov/pubmed/18504338.

72. Koshiol J, Rotunno M, Consonni D, et al. Chronic obstructive pulmonary disease and altered risk of lung cancer in a population-based case-control study. PLoS One 2009;4:e7380. Available at: http://www.ncbi.nlm.nih.gov/pubmed/19812684.

73. Turner MC, Chen Y, Krewski D, et al. Chronic obstructive pulmonary disease is associated with lung cancer mortality in a prospective study of never smokers. Am J Respir Crit Care Med 2007;176:285-290. Available at: http://www.ncbi.nlm.nih.gov/pubmed/17478615.

74. Turner-Warwick M, Lebowitz M, Burrows B, Johnson A. Cryptogenic fibrosing alveolitis and lung cancer. Thorax 1980;35:496-499. Available at: http://www.ncbi.nlm.nih.gov/pubmed/7434310.

75. Hubbard R, Venn A, Lewis S, Britton J. Lung cancer and cryptogenic fibrosing alveolitis. A population-based cohort study. Am J Respir Crit Care Med 2000;161:5-8. Available at: http://www.ncbi.nlm.nih.gov/pubmed/10619790.

76. Hughes JM, Weill H. Asbestosis as a precursor of asbestos related lung cancer: results of a prospective mortality study. Br J Ind Med 1991;48:229-233. Available at: http://www.ncbi.nlm.nih.gov/pubmed/2025587.

77. Chlebowski RT, Schwartz AG, Wakelee H, et al. Oestrogen plus progestin and lung cancer in postmenopausal women (Women's Health Initiative trial): a post-hoc analysis of a randomised controlled trial. Lancet 2009;374:1243-1251. Available at: http://www.ncbi.nlm.nih.gov/pubmed/19767090.

78. Tammemagi CM, Pinsky PF, Caporaso NE, et al. Lung cancer risk prediction: Prostate, Lung, Colorectal And Ovarian Cancer Screening Trial models and validation. J Natl Cancer Inst 2011;103:1058-1068. Available at: http://www.ncbi.nlm.nih.gov/pubmed/21606442.

79. Spitz MR, Hong WK, Amos CI, et al. A risk model for prediction of lung cancer. J Natl Cancer Inst 2007;99:715-726. Available at: http://www.ncbi.nlm.nih.gov/pubmed/17470739.

80. Cassidy A, Myles JP, van Tongeren M, et al. The LLP risk model: an individual risk prediction model for lung cancer. Br J Cancer 2008;98:270-276. Available at: http://www.ncbi.nlm.nih.gov/pubmed/18087271.

81. Cronin KA, Gail MH, Zou Z, et al. Validation of a model of lung cancer risk prediction among smokers. J Natl Cancer Inst 2006;98:637-640. Available at: http://www.ncbi.nlm.nih.gov/pubmed/16670389.

82. Bach PB, Kattan MW, Thornquist MD, et al. Variations in lung cancer risk among smokers. J Natl Cancer Inst 2003;95:470-478. Available at: http://www.ncbi.nlm.nih.gov/pubmed/12644540.

83. Henschke CI, Yankelevitz DF, Libby DM, et al. Survival of patients with stage I lung cancer detected on CT screening. N Engl J Med 2006;355:1763-1771. Available at: http://www.ncbi.nlm.nih.gov/pubmed/17065637.

84. Berg CD. Formidable challenges ahead for lung cancer screening. Oncology (Williston Park) 2012;26:182, 185. Available at: http://www.ncbi.nlm.nih.gov/pubmed/22489354.

85. Pedersen JH, Ashraf H, Dirksen A, et al. The Danish randomized lung cancer CT screening trial--overall design and results of the prevalence round. J Thorac Oncol 2009;4:608-614. Available at: http://www.ncbi.nlm.nih.gov/pubmed/19357536.

86. Berrington de Gonzalez A, Kim KP, Berg CD. Low-dose lung computed tomography screening before age 55: estimates of the mortality reduction required to outweigh the radiation-induced cancer risk. J Med Screen 2008;15:153-158. Available at: http://www.ncbi.nlm.nih.gov/pubmed/18927099.

87. Menezes RJ, Roberts HC, Paul NS, et al. Lung cancer screening using low-dose computed tomography in at-risk individuals: the Toronto experience. Lung Cancer 2010;67:177-183. Available at: http://www.ncbi.nlm.nih.gov/pubmed/19427055.

88. Swensen SJ, Jett JR, Hartman TE, et al. CT screening for lung cancer: five-year prospective experience. Radiology 2005;235:259-265. Available at: http://www.ncbi.nlm.nih.gov/pubmed/15695622.

89. Wilson DO, Weissfeld JL, Fuhrman CR, et al. The Pittsburgh Lung Screening Study (PLuSS): outcomes within 3 years of a first computed tomography scan. Am J Respir Crit Care Med 2008;178:956-961. Available at: http://www.ncbi.nlm.nih.gov/pubmed/18635890.

90. Sox HC. Better evidence about screening for lung cancer. N Engl J Med 2011;365:455-457. Available at: http://www.ncbi.nlm.nih.gov/pubmed/21714644.

91. Jett JR, Midthun DE. Screening for lung cancer: for patients at increased risk for lung cancer, it works. Ann Intern Med 2011;155:540-542. Available at: http://www.ncbi.nlm.nih.gov/pubmed/21893615.

92. Kim HY, Shim YM, Lee KS, et al. Persistent pulmonary nodular ground-glass opacity at thin-section CT: histopathologic comparisons. Radiology 2007;245:267-275. Available at: http://www.ncbi.nlm.nih.gov/pubmed/17885195.

93. Travis WD, Brambilla E, Noguchi M, et al. International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol 2011;6:244-285. Available at: http://www.ncbi.nlm.nih.gov/pubmed/21252716.

94. MacMahon H, Austin JHM, Gamsu G, et al. Guidelines for management of small pulmonary nodules detected on CT scans: a statement from the Fleischner Society. Radiology 2005;237:395-400. Available at: http://www.ncbi.nlm.nih.gov/pubmed/16244247.

95. Gould MK, Fletcher J, Iannettoni MD, et al. Evaluation of patients with pulmonary nodules: when is it lung cancer?: ACCP evidence-based clinical practice guidelines (2nd edition). Chest 2007;132:108S-130S. Available at: http://www.ncbi.nlm.nih.gov/pubmed/17873164.

96. Hansell DM, Bankier AA, MacMahon H, et al. Fleischner Society: glossary of terms for thoracic imaging. Radiology 2008;246:697-722. Available at: http://www.ncbi.nlm.nih.gov/pubmed/18195376.

97. Fischbach F, Knollmann F, Griesshaber V, et al. Detection of pulmonary nodules by multislice computed tomography: improved detection rate with reduced slice thickness. Eur Radiol 2003;13:2378-2383. Available at: http://www.ncbi.nlm.nih.gov/pubmed/12743736.

98. Valencia R, Denecke T, Lehmkuhl L, et al. Value of axial and coronal maximum intensity projection (MIP) images in the detection of pulmonary nodules by multislice spiral CT: comparison with axial 1-mm and 5-mm slices. Eur Radiol 2006;16:325-332. Available at: http://www.ncbi.nlm.nih.gov/pubmed/16086181.

99. Kawel N, Seifert B, Luetolf M, Boehm T. Effect of slab thickness on the CT detection of pulmonary nodules: use of sliding thin-slab maximum intensity projection and volume rendering. AJR Am J Roentgenol 2009;192:1324-1329. Available at: http://www.ncbi.nlm.nih.gov/pubmed/19380557.

100. Peloschek P, Sailer J, Weber M, et al. Pulmonary nodules: sensitivity of maximum intensity projection versus that of volume rendering of 3D multidetector CT data. Radiology 2007;243:561-569. Available at: http://www.ncbi.nlm.nih.gov/pubmed/17456878.

101. Park E-A, Goo JM, Lee JW, et al. Efficacy of computer-aided detection system and thin-slab maximum intensity projection technique in the detection of pulmonary nodules in patients with resected metastases. Invest Radiol 2009;44:105-113. Available at: http://www.ncbi.nlm.nih.gov/pubmed/19034026.

102. Jankowski A, Martinelli T, Timsit JF, et al. Pulmonary nodule detection on MDCT images: evaluation of diagnostic performance using thin axial images, maximum intensity projections, and computer-assisted detection. Eur Radiol 2007;17:3148-3156. Available at: http://www.ncbi.nlm.nih.gov/pubmed/17763856.

103. Rubin GD, Lyo JK, Paik DS, et al. Pulmonary nodules on multi-detector row CT scans: performance comparison of radiologists and computer-aided detection. Radiology 2005;234:274-283. Available at: http://www.ncbi.nlm.nih.gov/pubmed/15537839.

104. Fraioli F, Bertoletti L, Napoli A, et al. Computer-aided detection (CAD) in lung cancer screening at chest MDCT: ROC analysis of CAD versus radiologist performance. J Thorac Imaging 2007;22:241-246. Available at: http://www.ncbi.nlm.nih.gov/pubmed/17721333.

105. Sahiner B, Chan H-P, Hadjiiski LM, et al. Effect of CAD on radiologists' detection of lung nodules on thoracic CT scans: analysis of an observer performance study by nodule size. Acad Radiol 2009;16:1518-1530. Available at: http://www.ncbi.nlm.nih.gov/pubmed/19896069.

106. Das M, Muhlenbruch G, Heinen S, et al. Performance evaluation of a computer-aided detection algorithm for solid pulmonary nodules in low-dose and standard-dose MDCT chest examinations and its influence on radiologists. Br J Radiol 2008;81:841-847. Available at: http://www.ncbi.nlm.nih.gov/pubmed/18941043.

107. Lee HY, Goo JM, Lee HJ, et al. Usefulness of concurrent reading using thin-section and thick-section CT images in subcentimetre solitary pulmonary nodules. Clin Radiol 2009;64:127-132. Available at: http://www.ncbi.nlm.nih.gov/pubmed/19103341.

108. Kubo T, Lin P-JP, Stiller W, et al. Radiation dose reduction in chest CT: a review. AJR Am J Roentgenol 2008;190:335-343. Available at: http://www.ncbi.nlm.nih.gov/pubmed/18212218.

109. Lee JY, Chung MJ, Yi CA, Lee KS. Ultra-low-dose MDCT of the chest: influence on automated lung nodule detection. Korean J Radiol 2008;9:95-9101. Available at: http://www.ncbi.nlm.nih.gov/pubmed/18385555.

110. Funama Y, Awai K, Liu D, et al. Detection of nodules showing ground-glass opacity in the lungs at low-dose multidetector computed

tomography: phantom and clinical study. J Comput Assist Tomogr 2009;33:49-53. Available at: http://www.ncbi.nlm.nih.gov/pubmed/19188784.

111. Hein PA, Romano VC, Rogalla P, et al. Linear and volume measurements of pulmonary nodules at different CT dose levels - intrascan and interscan analysis. Rofo 2009;181:24-31. Available at: http://www.ncbi.nlm.nih.gov/pubmed/19085687.

112. Singh S, Pinsky P, Fineberg NS, et al. Evaluation of reader variability in the interpretation of follow-up CT scans at lung cancer screening. Radiology 2011;259:263-270. Available at: http://www.ncbi.nlm.nih.gov/pubmed/21248232.

113. Gierada DS, Pilgram TK, Ford M, et al. Lung cancer: interobserver agreement on interpretation of pulmonary findings at low-dose CT screening. Radiology 2008;246:265-272. Available at: http://www.ncbi.nlm.nih.gov/pubmed/18024436.

114. Henschke CI, Boffetta P, Gorlova O, et al. Assessment of lung-cancer mortality reduction from CT screening. Lung Cancer 2011;71:328-332. Available at: http://www.ncbi.nlm.nih.gov/pubmed/21168236.

115. van Klaveren RJ, Oudkerk M, Prokop M, et al. Management of lung nodules detected by volume CT scanning. N Engl J Med 2009;361:2221-2229. Available at: http://www.ncbi.nlm.nih.gov/pubmed/19955524.

116. Lopes Pegna A, Picozzi G, Mascalchi M, et al. Design, recruitment and baseline results of the ITALUNG trial for lung cancer screening with low-dose CT. Lung Cancer 2009;64:34-40. Available at: http://www.ncbi.nlm.nih.gov/pubmed/18723240.

117. Veronesi G, Bellomi M, Scanagatta P, et al. Difficulties encountered managing nodules detected during a computed tomography lung cancer screening program. J Thorac Cardiovasc Surg 2008;136:611-617. Available at: http://www.ncbi.nlm.nih.gov/pubmed/18805261.

118. Infante M, Cavuto S, Lutman FR, et al. A randomized study of lung cancer screening with spiral computed tomography: three-year results from the DANTE trial. Am J Respir Crit Care Med 2009;180:445-453. Available at: http://www.ncbi.nlm.nih.gov/pubmed/19520905.

119. Swensen SJ, Jett JR, Hartman TE, et al. Lung cancer screening with CT: Mayo Clinic experience. Radiology 2003;226:756-761. Available at: http://www.ncbi.nlm.nih.gov/pubmed/12601181.

120. Henschke CI, Yankelevitz DF, Naidich DP, et al. CT screening for lung cancer: suspiciousness of nodules according to size on baseline scans. Radiology 2004;231:164-168. Available at: http://www.ncbi.nlm.nih.gov/pubmed/14990809.

121. Henschke CI, Yankelevitz DF, Miettinen OS. Computed tomographic screening for lung cancer: the relationship of disease stage to tumor size. Arch Intern Med 2006;166:321-325. Available at: http://www.ncbi.nlm.nih.gov/pubmed/16476872.

122. Steele JD, Buell P. Asymptomatic solitary pulmonary nodules. Host survival, tumor size, and growth rate. J Thorac Cardiovasc Surg 1973;65:140-151. Available at: http://www.ncbi.nlm.nih.gov/pubmed/4682461.

123. Galante E, Reduzzi D, Gallus G, et al. The growth rate in the interpretation of the natural history of lung cancer. Tumori 1984;70:427-432. Available at: http://www.ncbi.nlm.nih.gov/pubmed/6506228.

124. Usuda K, Saito Y, Sagawa M, et al. Tumor doubling time and prognostic assessment of patients with primary lung cancer. Cancer 1994;74:2239-2244. Available at: http://www.ncbi.nlm.nih.gov/pubmed/7922975.

125. Arai T, Kuroishi T, Saito Y, et al. Tumor doubling time and prognosis in lung cancer patients: evaluation from chest films and

clinical follow-up study. Japanese Lung Cancer Screening Research Group. Jpn J Clin Oncol 1994;24:199-204. Available at: http://www.ncbi.nlm.nih.gov/pubmed/8072198.

126. Weiss W, Boucot KR, Cooper DA. The histopathology of bronchogenic carcinoma and its relation to growth rate, metastasis, and prognosis. Cancer 1970;26:965-970. Available at: http://www.ncbi.nlm.nih.gov/pubmed/5476797.

127. Swensen SJ, Viggiano RW, Midthun DE, et al. Lung nodule enhancement at CT: multicenter study. Radiology 2000;214:73-80. Available at: http://www.ncbi.nlm.nih.gov/pubmed/10644104.

128. Yi CA, Lee KS, Kim BT, et al. Tissue characterization of solitary pulmonary nodule: comparative study between helical dynamic CT and integrated PET/CT. J Nucl Med 2006;47:443-450. Available at: http://www.ncbi.nlm.nih.gov/pubmed/16513614.

129. Christensen JA, Nathan MA, Mullan BP, et al. Characterization of the solitary pulmonary nodule: 18F-FDG PET versus nodule-enhancement CT. AJR Am J Roentgenol 2006;187:1361-1367. Available at: http://www.ncbi.nlm.nih.gov/pubmed/17056930.

130. Schillaci O, Travascio L, Bolacchi F, et al. Accuracy of early and delayed FDG PET-CT and of contrast-enhanced CT in the evaluation of lung nodules: a preliminary study on 30 patients. Radiol Med 2009;114:890-906. Available at: http://www.ncbi.nlm.nih.gov/pubmed/19579015.

131. Bastarrika G, Garcia-Velloso MJ, Lozano MD, et al. Early lung cancer detection using spiral computed tomography and positron emission tomography. Am J Respir Crit Care Med 2005;171:1378-1383. Available at: http://www.ncbi.nlm.nih.gov/pubmed/15790860.

132. Fletcher JW, Kymes SM, Gould M, et al. A comparison of the diagnostic accuracy of 18F-FDG PET and CT in the characterization of solitary pulmonary nodules. J Nucl Med 2008;49:179-185. Available at: http://www.ncbi.nlm.nih.gov/pubmed/18199626.

133. Ashraf H, Dirksen A, Loft A, et al. Combined use of positron emission tomography and volume doubling time in lung cancer screening with low-dose CT scanning. Thorax 2011;66:315-319. Available at: http://www.ncbi.nlm.nih.gov/pubmed/21169285.

134. Ohno Y, Koyama H, Matsumoto K, et al. Differentiation of malignant and benign pulmonary nodules with quantitative first-pass 320-detector row perfusion CT versus FDG PET/CT. Radiology 2011;258:599-609. Available at: http://www.ncbi.nlm.nih.gov/pubmed/21273522.

135. Liu X, Liang M, Wang Y, et al. The outcome differences of CT screening for lung cancer pre and post following an algorithm in Zhuhai, China. Lung Cancer 2011;73:230-236. Available at: http://www.ncbi.nlm.nih.gov/pubmed/21168238.

136. CT Screening for lung cancer: diagnoses resulting from the New York Early Lung Cancer Action Project. Radiology 2007;243:239-249. Available at: http://www.ncbi.nlm.nih.gov/pubmed/17392256.

137. Eisenberg RL, Bankier AA, Boiselle PM. Compliance with Fleischner Society guidelines for management of small lung nodules: a survey of 834 radiologists. Radiology 2010;255:218-224. Available at: http://www.ncbi.nlm.nih.gov/pubmed/20308458.

138. Revel MP, Bissery A, Bienvenu M, et al. Are two-dimensional CT measurements of small noncalcified pulmonary nodules reliable? Radiology 2004;231:453-458. Available at: http://www.ncbi.nlm.nih.gov/pubmed/15128990.

139. Hanaoka T, Sone S, Takayama F, et al. Presence of local pleural adhesion in CT screening-detected small nodule in the lung periphery suggests noncancerous, inflammatory nature of the lesion. Clin Imaging 2007;31:385-389. Available at: http://www.ncbi.nlm.nih.gov/pubmed/17996600.

140. Ahn MI, Gleeson TG, Chan IH, et al. Perifissural nodules seen at CT screening for lung cancer. Radiology 2010;254:949-956. Available at: http://www.ncbi.nlm.nih.gov/pubmed/20177105.

141. Xu DM, van der Zaag-Loonen HJ, Oudkerk M, et al. Smooth or attached solid indeterminate nodules detected at baseline CT screening in the NELSON study: cancer risk during 1 year of follow-up. Radiology 2009;250:264-272. Available at: http://www.ncbi.nlm.nih.gov/pubmed/18984780.

142. Bankier AA, Tack D. Dose reduction strategies for thoracic multidetector computed tomography: background, current issues, and recommendations. J Thorac Imaging 2010;25:278-288. Available at: http://www.ncbi.nlm.nih.gov/pubmed/21042066.

143. Lee T-Y, Chhem RK. Impact of new technologies on dose reduction in CT. Eur J Radiol 2010;76:28-35. Available at: http://www.ncbi.nlm.nih.gov/pubmed/20643522.

144. Pontana F, Pagniez J, Flohr T, et al. Chest computed tomography using iterative reconstruction vs filtered back projection (Part 1): Evaluation of image noise reduction in 32 patients. Eur Radiol 2011;21:627-635. Available at: http://www.ncbi.nlm.nih.gov/pubmed/21053003.

145. Pontana F, Duhamel A, Pagniez J, et al. Chest computed tomography using iterative reconstruction vs filtered back projection (Part 2): image quality of low-dose CT examinations in 80 patients. Eur Radiol 2011;21:636-643. Available at: http://www.ncbi.nlm.nih.gov/pubmed/21080171.

146. Rami-Porta R, Ball D, Crowley J, et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the T descriptors in the forthcoming (seventh) edition of the TNM classification for lung cancer. J Thorac Oncol 2007;2:593-602. Available at: http://www.ncbi.nlm.nih.gov/pubmed/17607114.

147. Edge SB, Byrd DR, Compton CC. AJCC Cancer Staging Manual, 7th ed. New York: Springer; 2010.

148. Flieder DB, Vazquez M, Carter D, et al. Pathologic findings of lung tumors diagnosed on baseline CT screening. Am J Surg Pathol 2006;30:606-613. Available at: http://www.ncbi.nlm.nih.gov/pubmed/16699315.

149. Hall FM. Identification, biopsy, and treatment of poorly understood premalignant, in situ, and indolent low-grade cancers: are we becoming victims of our own success? Radiology 2010;254:655-659. Available at: http://www.ncbi.nlm.nih.gov/pubmed/20177083.

150. Raz DJ, Zell JA, Ou SHI, et al. Natural history of stage I non-small cell lung cancer: implications for early detection. Chest 2007;132:193-199. Available at: http://www.ncbi.nlm.nih.gov/pubmed/17505036.

151. McGarry RC, Song G, des Rosiers P, Timmerman R. Observation-only management of early stage, medically inoperable lung cancer: poor outcome. Chest 2002;121:1155-1158. Available at: http://www.ncbi.nlm.nih.gov/pubmed/11948046.

152. Bach PB, Jett JR, Pastorino U, et al. Computed tomography screening and lung cancer outcomes. JAMA 2007;297:953-961. Available at: http://www.ncbi.nlm.nih.gov/pubmed/17341709.

153. Carter D, Vazquez M, Flieder DB, et al. Comparison of pathologic findings of baseline and annual repeat cancers diagnosed on CT screening. Lung Cancer 2007;56:193-199. Available at: http://www.ncbi.nlm.nih.gov/pubmed/17239983.

154. Foy M, Yip R, Chen X, et al. Modeling the mortality reduction due to computed tomography screening for lung cancer. Cancer 2011;117:2703-2708. Available at: http://www.ncbi.nlm.nih.gov/pubmed/21656748.

155. Tabar L, Vitak B, Chen TH, et al. Swedish two-county trial: impact of mammographic screening on breast cancer mortality during 3

decades. Radiology 2011;260:658-663. Available at: http://www.ncbi.nlm.nih.gov/pubmed/21712474.

156. Mets OM, Buckens CF, Zanen P, et al. Identification of chronic obstructive pulmonary disease in lung cancer screening computed tomographic scans. JAMA 2011;306:1775-1781. Available at: http://www.ncbi.nlm.nih.gov/pubmed/22028353.

157. Jacobs PC, Gondrie MJ, Mali WP, et al. Unrequested information from routine diagnostic chest CT predicts future cardiovascular events. Eur Radiol 2011;21:1577-1585. Available at: http://www.ncbi.nlm.nih.gov/pubmed/21603881.

158. Sekikawa A, Curb JD, Edmundowicz D, et al. Coronary artery calcification by computed tomography in epidemiologic research and cardiovascular disease prevention. J Epidemiol 2012;22:188-198. Available at: http://www.ncbi.nlm.nih.gov/pubmed/22485011.

159. Molina JR, Yang P, Cassivi SD, et al. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc 2008;83:584-594. Available at: http://www.ncbi.nlm.nih.gov/pubmed/18452692.

160. Spira A, Ettinger DS. Multidisciplinary management of lung cancer. N Engl J Med 2004;350:379-392. Available at: http://www.ncbi.nlm.nih.gov/pubmed/14736930.

161. Manser R, Wright G, Hart D, et al. Surgery for early stage non-small cell lung cancer. Cochrane Database Syst Rev 2005. Available at: http://www.ncbi.nlm.nih.gov/pubmed/15674959.

162. Timmerman R, Paulus R, Galvin J, et al. Stereotactic body radiation therapy for inoperable early stage lung cancer. JAMA 2010;303:1070-1076. Available at: http://www.ncbi.nlm.nih.gov/pubmed/20233825.

163. Albain KS, Swann RS, Rusch VW, et al. Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial. Lancet 2009;374:379-386. Available at: http://www.ncbi.nlm.nih.gov/pubmed/19632716.

164. Crestanello JA, Allen MS, Jett JR, et al. Thoracic surgical operations in patients enrolled in a computed tomographic screening trial. J Thorac Cardiovasc Surg 2004;128:254-259. Available at: http://www.ncbi.nlm.nih.gov/pubmed/15282462.

165. Grannis FW. Can we avert the need for pneumonectomy by screening for lung cancer? Eur J Cardiothorac Surg 2004;25:296. Available at: http://www.ncbi.nlm.nih.gov/pubmed/14747135.

166. Henschke CI, McCauley DI, Yankelevitz DF, et al. Early Lung Cancer Action Project: overall design and findings from baseline screening. Lancet 1999;354:99-9105. Available at: http://www.ncbi.nlm.nih.gov/pubmed/10408484.

167. Sone S, Nakayama T, Honda T, et al. Long-term follow-up study of a population-based 1996-1998 mass screening programme for lung cancer using mobile low-dose spiral computed tomography. Lung Cancer 2007;58:329-341. Available at: http://www.ncbi.nlm.nih.gov/pubmed/17675180.

168. Flores RM, Park BJ, Dycoco J, et al. Lobectomy by video-assisted thoracic surgery (VATS) versus thoracotomy for lung cancer. J Thorac Cardiovasc Surg 2009;138:11-18. Available at: http://www.ncbi.nlm.nih.gov/pubmed/19577048.

169. Whitson BA, Groth SS, Duval SJ, et al. Surgery for early-stage non-small cell lung cancer: a systematic review of the video-assisted thoracoscopic surgery versus thoracotomy approaches to lobectomy. Ann Thorac Surg 2008;86:2008-2016; discussion 2016-2008. Available at: http://www.ncbi.nlm.nih.gov/pubmed/19022040.

170. Cheng D, Downey RJ, Kernstine K, et al. Video-assisted thoracic surgery in lung cancer resection: a meta-analysis and systematic review

of controlled trials. Innovations (Phila) 2007;2:261-292. Available at: http://www.ncbi.nlm.nih.gov/pubmed/22437196.

171. Detterbeck F. Thoracoscopic versus open lobectomy debate: the pro argument. Thorac Surg Sci 2009;6:Doc04. Available at: http://www.ncbi.nlm.nih.gov/pubmed/21289905.

172. Senan S, Palma DA, Lagerwaard FJ. Stereotactic ablative radiotherapy for stage I NSCLC: Recent advances and controversies. J Thorac Dis 2011;3:189-196. Available at: http://www.ncbi.nlm.nih.gov/pubmed/22263087.

173. Guckenberger M. What is the current status of Stereotactic body radiotherapy for stage I non-small cell lung cancer? J Thorac Dis 2011;3:147-149. Available at: http://www.ncbi.nlm.nih.gov/pubmed/22263080.

174. Anderson CM, Yip R, Henschke CI, et al. Smoking cessation and relapse during a lung cancer screening program. Cancer Epidemiol Biomarkers Prev 2009;18:3476-3483. Available at: http://www.ncbi.nlm.nih.gov/pubmed/19959698.

175. Townsend CO, Clark MM, Jett JR, et al. Relation between smoking cessation and receiving results from three annual spiral chest computed tomography scans for lung carcinoma screening. Cancer 2005;103:2154-2162. Available at: http://www.ncbi.nlm.nih.gov/pubmed/15825210.

176. Ashraf H, Tonnesen P, Holst Pedersen J, et al. Effect of CT screening on smoking habits at 1-year follow-up in the Danish Lung Cancer Screening Trial (DLCST). Thorax 2009;64:388-392. Available at: http://www.ncbi.nlm.nih.gov/pubmed/19052048.

177. Taylor KL, Cox LS, Zincke N, et al. Lung cancer screening as a teachable moment for smoking cessation. Lung Cancer 2007;56:125-134. Available at: http://www.ncbi.nlm.nih.gov/pubmed/17196298.

178. van den Bergh KAM, Essink-Bot ML, Borsboom GJJM, et al. Short-term health-related quality of life consequences in a lung cancer CT screening trial (NELSON). Br J Cancer 2010;102:27-34. Available at: http://www.ncbi.nlm.nih.gov/pubmed/19935789.

179. van den Bergh KA, Essink-Bot ML, Borsboom GJ, et al. Long-term effects of lung cancer computed tomography screening on health-related quality of life: the NELSON trial. Eur Respir J 2011;38:154-161. Available at: http://www.ncbi.nlm.nih.gov/pubmed/21148229.

180. Bunge EM, van den Bergh KAM, Essink-Bot M-L, et al. High affective risk perception is associated with more lung cancer-specific distress in CT screening for lung cancer. Lung Cancer 2008;62:385-390. Available at: http://www.ncbi.nlm.nih.gov/pubmed/18468717.

181. Silvestri GA. Screening for lung cancer: it works, but does it really work? Ann Intern Med 2011;155:537-539. Available at: http://www.ncbi.nlm.nih.gov/pubmed/21893614.

182. Croswell JM, Baker SG, Marcus PM, et al. Cumulative incidence of false-positive test results in lung cancer screening: a randomized trial. Ann Intern Med 2010;152:505-512. Available at: http://www.ncbi.nlm.nih.gov/pubmed/20404381.

183. Diederich S, Wormanns D, Semik M, et al. Screening for early lung cancer with low-dose spiral CT: prevalence in 817 asymptomatic smokers. Radiology 2002;222:773-781. Available at: http://www.ncbi.nlm.nih.gov/pubmed/11867800.

184. Gohagan JK, Marcus PM, Fagerstrom RM, et al. Final results of the Lung Screening Study, a randomized feasibility study of spiral CT versus chest X-ray screening for lung cancer. Lung Cancer 2005;47:9-15. Available at: http://www.ncbi.nlm.nih.gov/pubmed/15603850.

185. Kaneko M, Eguchi K, Ohmatsu H, et al. Peripheral lung cancer: screening and detection with low-dose spiral CT versus radiography. Radiology 1996;201:798-802. Available at: http://www.ncbi.nlm.nih.gov/pubmed/8939234.

186. Wiener RS, Schwartz LM, Woloshin S, Welch HG. Population-based risk for complications after transthoracic needle lung biopsy of a pulmonary nodule: an analysis of discharge records. Ann Intern Med 2011;155:137-144. Available at: http://www.ncbi.nlm.nih.gov/pubmed/21810706.

187. Henschke CI, Yip R, Yankelevitz DF, Miettinen OS. Computed tomography screening for lung cancer: prospects of surviving competing causes of death. Clin Lung Cancer 2006;7:323-325. Available at: http://www.ncbi.nlm.nih.gov/pubmed/16640803.

188. Bach PB, Cramer LD, Schrag D, et al. The influence of hospital volume on survival after resection for lung cancer. N Engl J Med 2001;345:181-188. Available at: http://www.ncbi.nlm.nih.gov/pubmed/11463014.

189. Silvestri GA, Handy J, Lackland D, et al. Specialists achieve better outcomes than generalists for lung cancer surgery. Chest 1998;114:675-680. Available at: http://www.ncbi.nlm.nih.gov/pubmed/9743149.

190. Stephan F, Boucheseiche S, Hollande J, et al. Pulmonary complications following lung resection: a comprehensive analysis of incidence and possible risk factors. Chest 2000;118:1263-1270. Available at: http://www.ncbi.nlm.nih.gov/pubmed/11083673.

191. Sone S, Takashima S, Li F, et al. Mass screening for lung cancer with mobile spiral computed tomography scanner. Lancet 1998;351:1242-1245. Available at: http://www.ncbi.nlm.nih.gov/pubmed/9643744.

192. Li F, Sone S, Abe H, et al. Lung cancers missed at low-dose helical CT screening in a general population: comparison of clinical, histopathologic, and imaging findings. Radiology 2002;225:673-683. Available at: http://www.ncbi.nlm.nih.gov/pubmed/12461245.

193. Armato SG, Li F, Giger ML, et al. Lung cancer: performance of automated lung nodule detection applied to cancers missed in a CT screening program. Radiology 2002;225:685-692. Available at: http://www.ncbi.nlm.nih.gov/pubmed/12461246.

194. Armato SG, 3rd, McLennan G, Bidaut L, et al. The Lung Image Database Consortium (LIDC) and Image Database Resource Initiative (IDRI): a completed reference database of lung nodules on CT scans. Med Phys 2011;38:915-931. Available at: http://www.ncbi.nlm.nih.gov/pubmed/21452728.

195. DeVita VT, Jr., Young RC, Canellos GP. Combination versus single agent chemotherapy: a review of the basis for selection of drug treatment of cancer. Cancer 1975;35:98-110. Available at: http://www.ncbi.nlm.nih.gov/pubmed/162854.

196. Folkman J. Seminars in Medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis. N Engl J Med 1995;333:1757-1763. Available at: http://www.ncbi.nlm.nih.gov/pubmed/7491141.

197. Swartz MA, Kristensen CA, Melder RJ, et al. Cells shed from tumours show reduced clonogenicity, resistance to apoptosis, and in vivo tumorigenicity. Br J Cancer 1999;81:756-759. Available at: http://www.ncbi.nlm.nih.gov/pubmed/10555742.

198. Patz EF, Black WC, Goodman PC. CT screening for lung cancer: not ready for routine practice. Radiology 2001;221:587-591. Available at: http://www.ncbi.nlm.nih.gov/pubmed/11719648.

199. Yoshizawa A, Motoi N, Riely GJ, et al. Impact of proposed IASLC/ATS/ERS classification of lung adenocarcinoma: prognostic subgroups and implications for further revision of staging based on analysis of 514 stage I cases. Mod Pathol 2011;24:653-664. Available at: http://www.ncbi.nlm.nih.gov/pubmed/21252858.

200. Russell PA, Wainer Z, Wright GM, et al. Does lung adenocarcinoma subtype predict patient survival?: a clinicopathologic study based on the new international association for the study of lung cancer/american thoracic society/european respiratory society

international multidisciplinary lung adenocarcinoma classification. J Thorac Oncol 2011;6:1496-1504. Available at: http://www.ncbi.nlm.nih.gov/pubmed/21642859.

201. Jett JR, Midthun DE. Commentary: CT screening for lung cancer--caveat emptor. Oncologist 2008;13:439-444. Available at: http://www.ncbi.nlm.nih.gov/pubmed/18448559.

202. van den Bergh KA, Essink-Bot ML, Bunge EM, et al. Impact of computed tomography screening for lung cancer on participants in a randomized controlled trial (NELSON trial). Cancer 2008;113:396-404. Available at: http://www.ncbi.nlm.nih.gov/pubmed/18484588.

203. Croswell JM, Kramer BS, Kreimer AR, et al. Cumulative incidence of false-positive results in repeated, multimodal cancer screening. Ann Fam Med 2009;7:212-222. Available at: http://www.ncbi.nlm.nih.gov/pubmed/19433838.

204. Sistrom CL, Dreyer KJ, Dang PP, et al. Recommendations for additional imaging in radiology reports: multifactorial analysis of 5.9 million examinations. Radiology 2009;253:453-461. Available at: http://www.ncbi.nlm.nih.gov/pubmed/19710005.

205. Berland LL, Silverman SG, Gore RM, et al. Managing incidental findings on abdominal CT: white paper of the ACR incidental findings committee. J Am Coll Radiol 2010;7:754-773. Available at: http://www.ncbi.nlm.nih.gov/pubmed/20889105.

206. Larke FJ, Kruger RL, Cagnon CH, et al. Estimated radiation dose associated with low-dose chest CT of average-size participants in the National Lung Screening Trial. AJR Am J Roentgenol 2011;197:1165-1169. Available at: http://www.ncbi.nlm.nih.gov/pubmed/22021510.

207. Brenner DJ. Radiation risks potentially associated with low-dose CT screening of adult smokers for lung cancer. Radiology 2004;231:440-445. Available at: http://www.ncbi.nlm.nih.gov/pubmed/15128988.

208. Mascalchi M, Belli G, Zappa M, et al. Risk-benefit analysis of X-ray exposure associated with lung cancer screening in the Italung-CT trial. AJR Am J Roentgenol 2006;187:421-429. Available at: http://www.ncbi.nlm.nih.gov/pubmed/16861547.

209. Goulart BH, Bensink ME, Mummy DG, Ramsey SD. Lung cancer screening with low-dose computed tomography: costs, national expenditures, and cost-effectiveness. J Natl Compr Canc Netw 2012;10:267-275. Available at: http://www.ncbi.nlm.nih.gov/pubmed/22308519.

210. Schweigert M, Dubecz A, Beron M, et al. Pulmonary infections imitating lung cancer: clinical presentation and therapeutical approach. Ir J Med Sci 2012. Available at: http://www.ncbi.nlm.nih.gov/pubmed/22592566.

211. Jacobs PC, Gondrie MJ, van der Graaf Y, et al. Coronary artery calcium can predict all-cause mortality and cardiovascular events on low-dose CT screening for lung cancer. AJR Am J Roentgenol 2012;198:505-511. Available at: http://www.ncbi.nlm.nih.gov/pubmed/22357989.

212. Duke SL, Eisen T. Finding needles in a haystack: annual low-dose computed tomography screening reduces lung cancer mortality in a high-risk group. Expert Rev Anticancer Ther 2011;11:1833-1836. Available at: http://www.ncbi.nlm.nih.gov/pubmed/22117150.

213. Castleberry AW, Smith D, Anderson C, et al. Cost of a 5-year lung cancer survivor: symptomatic tumour identification vs proactive computed tomography screening. Br J Cancer 2009;101:882-896. Available at: http://www.ncbi.nlm.nih.gov/pubmed/19690541.

214. McMahon PM, Kong CY, Bouzan C, et al. Cost-effectiveness of computed tomography screening for lung cancer in the United States. J Thorac Oncol 2011;6:1841-1848. Available at: http://www.ncbi.nlm.nih.gov/pubmed/21892105.

215. Chirikos TN, Hazelton T, Tockman M, Clark R. Screening for lung cancer with CT: a preliminary cost-effectiveness analysis. Chest 2002;121:1507-1514. Available at: http://www.ncbi.nlm.nih.gov/pubmed/12006436.

216. Mahadevia PJ, Fleisher LA, Frick KD, et al. Lung cancer screening with helical computed tomography in older adult smokers: a decision and cost-effectiveness analysis. JAMA 2003;289:313-322. Available at: http://www.ncbi.nlm.nih.gov/pubmed/12525232.

217. Marshall D, Simpson KN, Earle CC, Chu C. Potential cost-effectiveness of one-time screening for lung cancer (LC) in a high risk cohort. Lung Cancer 2001;32:227-236. Available at: http://www.ncbi.nlm.nih.gov/pubmed/11390004.

218. Wisnivesky JP, Mushlin AI, Sicherman N, Henschke C. The cost-effectiveness of low-dose CT screening for lung cancer: preliminary results of baseline screening. Chest 2003;124:614-621. Available at: http://www.ncbi.nlm.nih.gov/pubmed/12907551.

219. Lafata JE, Simpkins J, Lamerato L, et al. The economic impact of false-positive cancer screens. Cancer Epidemiol Biomarkers Prev 2004;13:2126-2132. Available at: http://www.ncbi.nlm.nih.gov/pubmed/15598770.